

**SLTB
2019**

**55th
SLTB
Scientific
Conference**

OCTOBER 2-4, SEVILLE



Welcome

We are pleased to welcome you to the SLTB 2019 meeting in Seville!

This year the University of Seville will host the official annual scientific event of the Society for Low Temperature Biology (SLTB). This annual meeting aims to promote the advancement of research into the effects of low temperatures on all types of organisms and their constituent cells, tissues and organs and technology related to the field of low temperature biology.

In addition, a Cell Therapy workshop has been organized in collaboration with the Stem Cell User Group (SCUG), representing stem cell therapy processing groups in the UK, and the Andalusian Initiative for Advanced Therapies, from Spain.

There is also a planned visit to the National Centre of Accelerators (CNA) on Thursday, before our traditional meeting dinner. Finally, Saturday morning delegates will enjoy this ancient city in a tour of Seville.

We hope you enjoy this year's conference!

SLTB 2019 Local Organizing Committee

- Ariadna Corral
- Ramón Risco
- Alberto Olmo
- Alejandro Lucas
- Patricia Vargas

Scientific Committee

- Prof. Christiani A. Amorim (Université Catholique de Louvain, Belgium)
- Dr. Estefania Paredes (University of Vigo, Spain)
- Prof. Elena Gonzalez (Technical University of Madrid, Spain)
- Dr. Ariadna Corral (University of Seville and CNA, Spain)
- Prof. Ramón Risco (University of Seville and CNA, Spain)
- Dr. Alberto Olmo (University of Seville, Spain)

SLTB Committee Organizers

- Alasdair Kay
- Glyn Stacey

SLTB 2019 SPONSORS



Cell Therapy Workshop

2nd October 2019

In collaboration with Stem Cells User Group (SCUG)
and the Andalusian Initiative for Advanced
Therapies

WEDNESDAY, OCTOBER 2, 2019

9.30 Registration

10.00 The Stem Cell User Group: An Introduction

Tamara Geach, Stem Cell User Group Organizer and chair

10.20 Failure of cryopreserved peripheral blood stem cells to ensure engraftment resolved by functional assays but not by post-thaw cell viability

Michael Watts (UCLH)

10.40 Cryostore CS5 Stability validations

Karen Buckland (Cell and Gene Therapy-GOS ICH, London)

11.00 Optimising freezing profiles

Allison Hubel (University of Minnesota)

11.20 Safe, affordable and standardized delivery of cryopreserved therapies

Roberto Hernán (Cellulis)

11.40 Coffee break

12.00 Dry or wet thawing; dare to compare

Kevin Jestice / Asymptote (Cambridge Hospital, UK)

12.20 Influence of cooling rate on clonogenic cell recovery

Stephanie Ingleton (UCLH, London)

12.40 Biodock and maximising cryogenic storage capacity

Kieron Edwards-Pritchard (Biodock)

13.00 Bone marrow stem cell and ischemic stroke

Francisco Moniche (HU Virgen del Rocío)

13.20 3D Bioprinting of skeletal muscle constructs with different bioink and the use of bioreactor for stimulating

Francisco José Calero (HU Virgen del Rocío – IBIS)

13.40 Cell therapies within the Andalusian Public Healthcare System

Iñaki Roke Oruezabal (IATA)

14.00 Lunch

15.00	Storage and transport of cells and tissues at room temperature Mick McClean (Atelerix)
15.20	General Electric Healthcare John Morris (GE)
15.40	Changes in viability markers of haematopoietic stem cells following long-term cryopreservation Lisa O'Connor (OLCHC Crumlin)
16.00	Cryopreservation and CliniMACS Prodigy: Regenerating virus specific T cells from frozen DLIs Michael Schenk (Miltenyi Biotec in Collaboration with Dr. Sandra Loaiza, John Goldman Centre for Cellular Therapy, Hammersmith Hospital)
16.20	Demonstration of the Zip Thaw thawer Terry McKindley (Deva-Medical)
16.40	Open Discussion
17.00	Meeting Close

STLB Meeting

3-4th October 2019

THURSDAY, OCTOBER 3, 2019

8.00 Registration

WELCOME AND OPENING REMARKS

- 8.30 Pr. Ramón Risco (Seville, Spain)
Professor of the University of Seville
- 8.40 Dr Glyn Stacey (Potters Bar, United Kingdom)
President of the Society of Low Temperature Biology

Chair: Dr Glyn Stacey (Barley, United Kingdom)

STEM CELLS CRYOPRESERVATION - SPONSORED BY LIFE SCIENCE GROUP



- 8.50 Cell shipment without a cold chain
E. Buick (Life Science Group Ltd)
- 9.00 New cryopreservation technology of HMSCS – first preclinical results using DMSO containing or DMSO-free medium
M. Jandová (Czech Republic)
- 9.20 Different aspects of clinical-grade processing of multipotent mesenchymal stromal cells: focusing the therapeutic properties depending on the cell source, hypothermic storage and cryopreservation conditions
Y. Petrenko (Czech Republic)

Chair: Dr Ramón Risco and Dr Ariadna Corral (Seville, Spain)

REPRODUCTIVE CELLS AND TISSUES CRYOPRESERVATION: Keynote lecture I

- 9.40 Cryopreservation of ovarian tissue: an emerging technology for female germline preservation of endangered species and autochthone breeds
Dr Christiani Amorim (Université Catholique de Louvain, Brussels, Belgium)

10.10 Coffee break, poster presentations and sponsor exhibitions

REPRODUCTIVE CELLS AND TISSUES CRYOPRESERVATION: Keynote lecture II

- 10.40 Vitricification of human eggs for fertility preservation - hype or hope?
Dr Zuzana Holubcova (Faculty of Medicine, University of Masaryk, Brno, Czech Republic)

Oral Presentations

- 11.10 Human oocytes and zygotes are ready for ultra-fast vitrification after 2 minutes of exposure to standard CPA solutions
Dr Miguel Gallardo (Unidad Hospitalaria Malo Clinic, Lisbon, Portugal)

- 11.30 Fertilization Rate and further embryo development of human vitrified MII oocytes matured in vitro from GV stage oocytes in medium supplemented with insulin growth factor-I
T. Yurchuk (Ukraine)
- 11.50 Vitrification of human oocytes: the relationship between incubation timing before freezing and after thawing with state of thawed oocytes and utilization effectivity
I. Kratochvilova (Czech Republic)

12.10 Lunch/AGM

Chair: to be confirmed

ANIMAL EMBRYO CRYOPRESERVATION: Keynote lecture

- 13.20 From the Ocean to the freezer and back
Dr Estefania Paredes (Universidade de Vigo, Vigo, Spain)

Oral Presentations

- 13.50 Cryopreservation of marine resources and its application on aquaculture industry and biodiversity conservation
P. Heres (Spain)

Chair: Dr Milos Faltus (Prague, Czech Republic)

PLANT CRYOPRESERVATION: Keynote lecture

- 14.10 Genetic and epigenetic stability after cryopreservation: is there real concern? Plant cases
Dr Elena Gonzalez de Benito (Technical University of Madrid, Madrid, Spain)

Oral presentations

- 14.40 Droplet vitrification: a success story for multiple crops, now including coconut
H. Wilms (Belgium)
- 15.00 New Zealand's Actinidia sp. germplasm conservation using cryopreservation
J. Nadarajan (New Zealand)
- 15.20 An ultracool desert garden
R. Folgado (USA)

15.40 Coffee break, poster presentations and sponsor exhibitions

Chair: Dr Christiani Amorim (Brussels, Belgium)

BLOOD AND BLOOD VESSELS CRYOPRESERVATION: Keynote lecture

- 16.10 Recovery and post-thaw assessment of human umbilical cord blood cryopreserved in quality control segments and bulk sample
Dr Peter Kilbride (General Electric Healthcare, Cambridge, United Kingdom)

Oral presentations

- 16.40 Assessment of viability of long-term stored cryopreserved allogeneic venous grafts using vital fluorescence dyes and confocal microscopy
P. Mericka (Czech Republic)
- 17.00 Efficacy of a Novel Precision Dry Thawing System: Preservation of Plasma Anti/Coagulation Proteins Necessary for Use in the Clinic.
F. Bischoff (United States)
- 17.20 Departure for a visit to the ETSI and the CNA by bus
- 20.00 Dinner and award ceremony

FRIDAY, OCTOBER 4, 2019

- 8.00 Registration

Dr Alasdair Kay (York, United Kingdom)

PHYSICS AND ENGINEERING APPLIED TO CRYOPRESERVATION: Oral presentations

- 8.30 Towards biobanking of tissue-engineered products
B. Glasmacher (Leibniz Universität Hannover, Hannover, Germany)
- 8.50 A meta-analysis of the Boyle van't Hoff relation and new developments in osmotic regulation modeling
D. Olver (Canada)
- 9.10 Post cryopreservation delayed cell death in hepatic organoids is linked to cell-matrix interactions
M. Awan (United Kingdom)
- 9.30 Computational modelling and optimisation of cryopreservation protocols using BioDynaMo
R. Bauer (United Kingdom)
- 9.50 Improving sample identification and reducing risks during cryostorage of vitrified gametes and embryos using radio frequency identification (RFID) tags that operate while samples are immersed in liquid nitrogen
G. Palmer (United Kingdom)
- 10.10 Thermal analysis methods as a tool for development of cryopreservation protocols
M. Faltus (Czech Republic)
- 10.30 Coffee break, poster presentations and sponsor exhibitions

Birgit Glasmacher (Hannover, Germany)

CRYOPROTECTIVE AGENTS: Oral presentations

- 11.00 The cryoprotectant DMSO. Identifying problems and developing its safe and effective use

- I. Buriak (Ukraine)
- 11.20 Fibroblast cryopreservation in nanocrystalline cerium dioxide containing media
O. Polivanova (Ukraine)
- 11.40 New cryoprotectants based on natural deep eutectic solvents
A.R. Jesus (Portugal)
- 12.00 Fructose oligosaccharides as a novel cryoprotectant for mammalian cells
P. Kilbride (General Electric Healthcare, Cambridge, United Kingdom)
- 12.20 Critical defects in cryopreserved cell nuclei: DNA structure changes
I. Kratochvilova (Czech Republic)

12.40 Lunch

Chair: Dr Alberto Olmo (Seville, Spain)

ORGAN TRANSPLANTATION: Keynote lectures - SPONSORED BY PLANER



- 13.40 The pharmaco-physiology of surviving hypothermia in the organ transplant pathway
Dr Barry Fuller (UCL Medical School, London, United Kingdom)
- 14.10 An "Off The Shelf" Cryopreservable Regenerative Medicine Cell Therapy (cATMP) For
Treating Patients With Liver Failure - UCL BioArtificial Liver Machine
Dr Clare Selden (UCL Medical School, London, United Kingdom)

APPLICATION OF "CRYO" IN CELLS: Keynote lecture

- 14.40 Cells surviving the ice age
Dr Birgit Glasmacher (Leibniz Universität Hannover, Hannover, Germany)

Oral Presentations

- 15.10 Freezing levels determine successful cryoablation of Ehrlich carcinoma cells
A. Goltsev ((Ukraine)

15.30 Coffee break, poster presentations and sponsor exhibitions

Chair: Dr Ramón Risco (Seville, Spain) and Dr Ariadna Corral (Seville, Spain)

ORGAN CRYOPRESERVATION: Keynote lecture

- 16.00 Myometrial function and viability following controlled-rate cryopreservation of ovine
uteri
Dr. Juan Hernandez-Medrano (Nottingham University, United Kingdom)

Oral Presentations

- 16.30 Design of a biological cryoprotector based on on antifreeze proteins linked to a protein
transfection domain
Ramón Risco (Spain)

FINAL REMARKS AND CLOSING CEREMONY

17.00 Prof Christiani Amorim (Université Catholique de Louvain, Brussels, Belgium)
Dr Ariadna Corral (University of Sevilla, Sevilla, Spain)

SATURDAY, OCTOBER 5, 2019

11.00 Sevilla City Tour (2 hours)

Cell Therapy Workshop

Wednesday, October 2

The Stem Cell User Group: An Introduction

Tamara Geach¹

¹The London Clinic, Stem Cell User Group (SCUG)

The Stem Cell User Group (SCUG) has been running since 2005 and was formed to respond to new legislation in the UK, namely the Human Tissue Act which arose in 2006 to regulate the bone marrow and stem cell transplantation sectors. It originally was geared toward helping laboratory and quality managers toward compliance and started as a small meeting comprised of centres from the Midlands and the South East of England. The format has always been to have two meetings per year in order for the community to have access to the most recent findings and opinions in the field. From the original 10 members there is now a large online e-mail based forum of 250 and there are still two meetings held per annum with a different host each meeting. The SCUG now has national exposure and has been held in centres throughout the UK and Ireland. This year is its first foray outside of the United Kingdom for The Society for Low Temperature Biology in Seville in October but it intends to continue in this vein with the June 2020 SCUG to be hosted in Cologne.

It is a not-for-profit organisation and seeks to be run at no cost to its members. Both the HTA and JACIE recognise that the meeting is the most applicable meeting for scientists, quality managers and all staff involved in stem cell and bone marrow transplantation for educational and CPD purposes. Recently the huge interest in cellular therapies has had an impact on the diverse nature of presentations this meeting has to offer. It is an evolving meeting and one that is growing in interest.

Failure of cryopreserved peripheral blood stem cells to ensure engraftment resolved by functional assays but not by post-thaw cell viability

Michael Watts¹, Stuart Ings¹, Carmen Balsa¹

¹Wolfson Cellular Therapy Unit, University College London Hospitals, London, UK

The majority of patients receiving cryopreserved haematological stem cell support after myeloablative therapy recover an absolute neutrophil count (ANC) of $0.5 \times 10^9/\text{l}$ within 14 days post-transplant^{1,2} and post-thaw viable CD34+ cell counts often used to test the product for cell potency³. In an engraftment incident in 2013 however, the ANC recovery of eight children receiving stem cell support was > 30 days despite adequate viable CD34+ cell doses over $2.5 \times 10^6/\text{kg}$ in all cases⁴. No cells remained from the affected patients but five stored clinical stem cell products were tested and showed similar viable CD34+ cell recovery with a median (range) of 82%(65-95%). Colony Forming Unit-Granulocyte/Monocyte, (CFU-GM) colonies were additionally performed as a functional assay and failed to grow or were extremely poor in all samples. To test the freeze protocol used, individual stem cell harvests were prepared at clinical scale, divided in three, and cryopreserved in parallel in two laboratories. In one centre, the controlled rate freeze (CRF) protocol used for the patients and by 'passive' freezing¹ at -800C in both centres. The freeze rate of the samples using the passive method was -10C/min and CFU-GM recovery was equivalent between both laboratories with a median (range) of 70% (47-118%) for all samples. In contrast, the freeze rate of the CRF samples was -50C/min and no CFU-GM growth was detected in four experiments. Retrospective patient review 2003-2014 showed a post-transplant median ANC recovery of 13 days but in 26/181 (14%) was > 30 days. The passive freeze method was adopted in 2015 and the median ANC of the next 35 patients was 11.5 days, with none over 18 days ($P < 0.0001$) confirming clinical potency with the slower freeze rate⁴. The potential of sub-lethal freeze damage and 'viable' but non-functional cells has important implications for the QC of all cryopreserved cell therapies.

1. Watts, M. J., Ings, S. J., Balsa, C., Antonio, A., Hack, S., Linch, D. C. (2016) 'Re-evaluation of progenitor thresholds and expectations for haematopoietic recovery based on an analysis of 810 autologous transplants: Implications for quality assurance' Br J Haematol 175(4) pp. 673-676.
2. Watts and Linch (2016) 'Optimisation and quality control of cell processing for autologous stem cell transplantation' Br J Haematol 175(5) pp. 771-783
3. Yang, H., Acker, J.P., Cabuhat, M., Letcher, B., Larratt, L. & McGann, L.E. (2005) 'Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment.' Bone Marrow Transplant, 35, 881-887.
4. Morgenstern, D.A., Brocklesby, M., Ahsan, G., Goulden, N., Ings, S.J., Balsa, C. & Watts, M. (2016) 'Post-Thaw Viability Of Cryopreserved Peripheral Blood Stem Cells (PBSC) Does Not Guarantee Functional Activity: Important Implications For Quality Assurance Of Stem Cell Transplant Programmes'. Br J Haematol 174(3) pp. 942-951

Cryostor CS5 Stability Validations

KF Buckland^{1,2,3}, D Leon-Rico^{1,2,3}, I Pereira^{1,2,3}, E Armenteros-Monterroso^{1,2,3}, A Diasakou^{1,2,3}, C Booth^{1,2,3}, HB Gaspar^{1,2,3}, AJ Thrasher^{1,2,3}

¹Great Ormond Street Institute of Child Health, University College London, UK

²Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

³NIHR Great Ormond Street Hospital Biomedical Research Centre

Autologous gene modified CD34+ haematopoietic stem cells are used to correct monogenic disorders of the immune system. These advanced therapy medicinal products (ATMPs) are typically cryopreserved and stored for >1 month prior to infusion. We have developed a technique for effective formulation in a novel cryoprotectant Cryostor CS5® (CS5), which contains 5% DMSO and is manufactured by BlueLife solutions. CS5 has been accepted as a novel excipient for >10 clinical trials globally and to date >20 ATMPs formulated in CS5 have been infused in patients at Great Ormond Street Hospital (GOSH).

Currently we have two controlled rate freezer programs in use for CD34+ ATMP clinical trials and we have carried out similar validations for both programs. Cells are formulated in 20 mL +/- 1.5mL per bag at a concentration of $2-17.5 \times 10^6$ TNC/mL. Cells were filled into Kryosure 20F bags (Saint Gobain), overwrapped, cryopreserved and stored in Vapour Phase LN2. Stability validations have shown CD34+ ATMP formulated and stored in this way are stable, with similar values for cell number, viability, potency and colony forming units (CFUs) evaluated at 1, 3, 6 and 12 months post cryopreservation. Sterility tests were also negative at all time-points assayed.

The data presented supports the ongoing use of CS5 as a cryoprotectant for CD34+ ATMPs and we propose the implementation as a convenient excipient for other 'routine' bone marrow transplant (BMT) products.

Dry or wet thawing; dare to compare

Kevin Jestice

The requirements by regulators for therapeutic laboratories to provide evidence of thawing has prompted a re-examination of thawing methodology. The world has moved on from simple waterbath thawing. A number of new 'dry' and automated cell thawing devices have come onto the market. All will need GMP validation studies to back up claims of action by the manufacturer. These are clinical devices that can have very serious adverse effects on cells if incorrectly used. Patient safety is of primary concern. This presentation concentrates on a real world comparison of large volume cellular thawing using a waterbath and a newer automated 'dry' system.

There is a wish list of specifications for an automated thawing device used in the treatment of patients. These specifications must conform to current regulations. Of specific interest is the Asymptote Via-Thaw machine which seems to cover all the requirements.

Influence of cooling rate on clonogenic cell recovery

Stephanie Ingleton¹, Michael Watts¹, Carmen Balsa¹

¹Wolfson Cellular Therapy Unit, University College London Hospitals, London, UK

Haematopoietic stem cells (HPC) are routinely cryopreserved from patients to provide haematological rescue of planned myeloablative therapies. The procedure is widely successful but there is no standard cryopreservation method and this can introduce risk. For example freeze rates of -50°C/min or more in controlled rate freeze (CRF) protocols compensated for the latent heat of fusion or simple ramp steps have resulted in the loss of Colony Forming Unit-Granulocyte/Monocyte, (CFU-GM) activity and engraftment failure:^{1,2,3} prompting further exploration of the effect of freeze rate on CFU-GM survival. No CFU-GM colonies were recovered at a freeze rate of -100°C/min in 6 HPC samples tested confirming the fast freeze risk. The effect of slowing the freeze rate was then studied. In four clinical scale HPC experiments, the starting product was divided into four 100ml samples and placed in a -80°C mechanical freezer ('passive freezing'⁴). The freeze rate was reduced by increasing the total freeze volume progressively by placing the first 100ml sample in the freezer alone and stacking the remaining three on 100ml cryoprotectant bags of 1 x 100ml, 3 x 100ml or 7 x 100ml. The increased volume slowed the sample freeze rate from

-1.20°C/min to -0.90°C/min, 0.50°C/min and 0.30°C/min respectively. The expected mean $\pm$ 1SD (range) recovery of CFU-GM of HPC clinical samples is $68 \pm 27\%$ (27-104%) at our centre 5 and was $68 \pm 27\%$ (27-104%) for all samples tested at all freeze rates with no pattern of GM-CFC loss at the lowest freeze rate. A recommended freeze rate of between -10°C/min to -30°C/min has been proposed for HPC for clinical use but freeze rates as low as -0.30°C/min were not detrimental to CFU-GM survival in this study.

1. Abrams, R.A., Glaubiger, D., Simon, R., Lichter, A. & Deisseroth, A.B. (1980) 'Haemopoietic recovery in Ewing's sarcoma after intensive combination therapy and autologous marrow infusion.' *Lancet*, 2, 385-389
2. Gorin, N.C., Douay, L., David, R., Stachowiak, J., Parlier, Y., Oppenheimer, M., Najman, A. & Duhamel, G. (1983) 'Delayed kinetics of recovery of haemopoiesis following autologous bone marrow transplantation. The role of excessively rapid marrow freezing rates after the release of fusion heat.' *Eur J Cancer Clin Oncol*, 19, 485-491
3. Morgenstern, D.A., Brocklesby, M., Ahsan, G., Goulden, N., Ings, S.J., Balsa, C. & Watts, M. (2016) 'Post-Thaw Viability Of Cryopreserved Peripheral Blood Stem Cells (PBSC) Does Not Guarantee Functional Activity: Important Implications For Quality Assurance Of Stem Cell Transplant Programmes'. *Br J Haematol* 174(3) pp. 942-951
4. Watts, M. J., Ings, S. J., Balsa, C., Antonio, A., Hack, S., Linch, D. C. (2016) 'Re-evaluation of progenitor thresholds and expectations for haematopoietic recovery based on an analysis of 810 autologous transplants: Implications for quality assurance' *Br J Haematol* 175(4) pp. 673-676.
5. Watts and Linch (2016) 'Optimisation and quality control of cell processing for autologous stem cell transplantation' *Br J Haematol* 175(5) pp. 771-783

Biodock and maximising cryogenic storage capacity

Kieron Edwards-Pritchard¹

¹BioDock, Nottingham, United Kingdom

BioDock is an industry leader in the storage of biological materials. With over 17 years of specialist biobanking experience, BioDock has developed a range of services to help clients such as NHS trusts, research institutions, and pharmaceutical and biotech manufacturers to maximise their storage capacity. With resources such as a dedicated medical courier service, multiple storage sites and readily-available backup equipment, each service is bespoke depending on the needs of the client and their samples. In order to design each service, BioDock considers the 'STEEP' principles to ensure the services provided are of the highest quality.

1. Campbell, Lori D., et al. "The 2018 Revision of the ISBER Best Practices: Summary of Changes and the Editorial Team's Development Process." *Biopreservation and Biobanking*, vol. 16, no. 1, Feb. 2018, pp. 3–6, 10.1089/bio.2018.0001. Accessed 12 Sept. 2019.
2. FACT, and JACIE. *HEMATOPOIETIC CELLULAR THERAPY for Product Collection, Processing, and Administration SEVENTH EDITION 7.0*. Mar. 2018.

3D Bioprinting of skeletal muscle constructs with different bioink and the use of bioreactor for stimulating

Francisco José Calero¹

¹Hospital Universitario Virgen del Rocío – IBIS

Tissue engineering technology has recently expanded into various areas due to increased demand for biocompatibility, that is, tissue repair and regeneration using natural biomaterials. Bioprinting (Fig. 1A) has the potential to deposit various materials and cells in a 3D matrix by layer-by layer deposition and mimic biological organs or tissues. Tissue engineering is a promising approach to repair tendon and muscle when natural healing fails, however there is no consensus to reconstruct musculo-eskeletal tissue. Here, we report our experience in bioprinting and the different phases of this technique to reconstruct musculo-eskeletal tissue and its stimulation with bioreactor.

A scaffold (Fig. 1B) was designed with a rhombus in its interior to provide a support to the cellularized hydrogel. Four hydrogels were made based on collagen and with a cell density of 40×10^6 cells/mL. After 3 weeks of culture, the bioprinted scaffolds were fixed for their later staining with Hematoxylin-Eosin and with AMLs. Moreover, we stimulate our bioprinted scaffolds with mechanical and electrical stimulation increasing the stimulus by week for 3 weeks (Fig. 1C).

Sixteen scaffolds (Fig. 1B) have been created by bioprinting and the good histological behaviour of the collagen and alginate bioink has been demonstrated. This bioink showed a cellular viability of 63%, reaching 90% of viability in 50% of the scaffolds manufactured with this bioink. The collagen bioink presented a viability of 24%; the collagen and matrigel bioink 40% of viability and MEC 50% of viability. The staining with AMLS has been visualized (Fig. 1D), therefore the initial differentiation to skeletal muscle has been demonstrated.

We tested 4 bioinks, we have demonstrated that collagen and alginate bioink showed more cellular viability than the other bioinks. The staining has been achieved by using antibody of specific muscle proteins.

Cell therapies within the Andalusian Public Healthcare System

Ángela Ponce Polo¹, Álvaro Ritoré¹, Roke Iñaki Oruezabal¹

¹Andalusian Network for Design and Translation of Advanced Therapies. Seville, Spain

The Andalusian Network for Design and Translation of Advanced Therapies (AND&TAT) was created in October 2008, promoted by the then Regional Ministries of Health and of Economy, Innovation and Science with the vision for Andalusia to aspire to play a relevant role in the field of advanced therapies, so that research, development and innovation in this field become the drivers for scientific progress, improvement of health and future social and economic development.

AND&TAT represents an innovative and singular technological maturation platform with the mission of promoting the development of novel cell and gene therapies and to incorporate them into the public healthcare system in Andalusia. Together with multiple stakeholders, AND&TAT has developed a Research & Development program around cell-based therapies. More than 900 patients have either participated in the 26 clinical trials we have promoted so far or have received, an ATMP manufactured, according to GMP, in our public network of laboratories. AND&TAT has provided its experience in activities such as advising researchers in regulatory aspects, setting up the manufacturing of ATMPs, designing and monitoring Clinical Trials, identifying industrial partners and generating new public-private partnerships, among others.

Cryopreservation is a small but essential process at some points of certain ATMP supply chain, since it allows to maintain a low temperature at which the ATMPs' therapeutic properties can be preserved and their usually short self-life extended. In this regard, not only is cryopreservation a crucial step in the storage of ATMPs, but also a critical need for transport and distribution of starting materials/finished products between the different supply chain sites (procurement, manufacturing and administration site).

AND&TAT has been working on developing innovative solutions in recent years. Two national projects in collaboration with biotech companies have been funded within the Spanish "Retos-Colaboración" national programme. The first of these projects aims to test the use of the disruptive cryopreservation technology developed by Cellulis S.L., LimboTM, on ATMPs manufactured within the AND&TAT's GMP laboratories network. The second project's main objective is to evaluate a novel platelet lysate supplement developed within the Andalusian Public Health Care System (International patent application number: PCT/ES2018/070370) as a substitute of FBS in the cryopreservation media.

Storage and transport of cells and tissues at room temperature

Stephen Swioklo¹, Dean Hallam¹, Che Connon^{1, 2}, Mick McLean¹

¹Atelerix Ltd, Cambridge, UK

²Newcastle University, Newcastle upon Tyne, UK

Atelerix has developed a method of encapsulating human cells and tissues in an alginate hydrogel that makes them practical to use, adaptable and easy to store and transport – even at room temperature. Used as a method of cell storage and transport, it overcomes the acknowledged problems associated with cryo-shipping. Cells are encapsulated by *in situ* formation of the gel for shipping in plates, vials or beads, and can be rapidly released from the gel by the addition of a simple buffer.

This talk will present several case studies of using the encapsulation approach for hypothermic storage of cells used for fresh cell therapies and for cell models used as research tools for drug discovery and testing.

1. Swioklo, S., Connon, C.J. (2016) Keeping cells in their place: the future of stem cell encapsulation. *Expert Opinion Biol. Ther.*
2. Swioklo, S., Ding, P., Pacek, A.J., Connon, C.J. (2016) Process parameters for the high-scale production of alginate-encapsulated stem cells for storage and distribution throughout the cell therapy supply chain. *Process Biochemistry*
3. Swioklo, S., Constantinescu, A., Connon, C.J. (2016) Alginate-Encapsulation for the Improved Hypothermic Preservation of Human Adipose-Derived Stem Cells. *Stem Cells Translational Medicine*

Changes in viability markers of haematopoietic stem cells following long-term cryopreservation

Lisa O'Connor¹, Nicola Gardiner¹, Catherine Blackwell¹, Karen Keane¹, Mary Neylon¹, Nataslie Maloney¹, Hayley Foy-Stones¹, Eoin Kenny¹, Ashique Khan¹, Rob Henderson¹, Paul Brown¹, Patrick Hayden¹

¹Cryobiology Laboratory Stem Cell Facility, Dept. of Academic Haematology, Trinity College, St. James's Hospital, Dublin 8

Hematopoietic stem cell (HSC) products for autologous transplantation are cryopreserved and stored in vapour phase liquid nitrogen (-197°C to -150°C). There is no consensus on a universal expiry date. Forty-four peripheral blood stem cell (PBSC) products that were in long-term storage for between 1 and 22 years and fifty-eight autologous PBSC products in storage for less than 1 year were included. A post-thaw sample was taken directly from the clinical product bag for analysis. Percentage Viability (PV), viable CD34+ cell count (VCD34) and progenitor cultures (CFU-GM/BFU-E) were assessed. Analysis of these one hundred and two HSC products revealed a statistically significant decrease in PV, VCD34 and progenitors over time. Post-thaw VCD34 and progenitor culture results were not shown to be better indicators of neutrophil and platelet engraftment than the results at harvest. An approximate 2% reduction in VCD34 per year of storage was observed, allowing for prediction of the post-thaw VCD34 and could aid in the determination of an expiry date for each product.

1. Fernyhough LJ, Buchan VA, McArthur LT, Hock BD. Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years. *Bone Marrow Transplant* 2013; 48(1): 32-35. e-pub ahead of print 2012/06/05; doi: 10.1038/bmt.2012.97
2. Spurr EE, Wiggins NE, Marsden KA, Lowenthal RM, Ragg SJ. Cryopreserved human haematopoietic stem cells retain engraftment potential after extended (5-14 years) cryostorage. *Cryobiology* 2002; 44(3): 210-217. e-pub ahead of print 2002/09/19
3. Vosganian GS, Waalen J, Kim K, Jhatakia S, Schram E, Lee T et al. Effects of long-term cryopreservation on peripheral blood progenitor cells. *Cytotherapy* 2012; 14(10): 1228-1234. e-pub ahead of print 2012/08/21; doi: 10.3109/14653249.2012.706707
4. Winter JM, Jacobson P, Bullough B, Christensen AP, Boyer M, Reems JA. Long-term effects of cryopreservation on clinically prepared hematopoietic progenitor cell products. *Cytotherapy* 2014; 16(7): 965-975. e-pub ahead of print 2014/06/10; doi: 10.1016/j.jcyt.2014.02.005
5. Watts MJ, Linch DC. Optimisation and quality control of cell processing for autologous stem cell transplantation. *Br J Haematol* 2016; 175(5): 771-783. e-pub ahead of print 2016/10/18; doi: 10.1111/bjh.14378

Isolation of virus-specific T cells after cryogenic storage for treatment of high viremia in immunocompromised patients

Michael Schenk¹, Shab Uddin², Emma Bray², Sima Hirani¹, Katharina Krämer³, Antonio Di Rocco¹, John Campbell⁴, Sandra Loaiza²

¹Miltenyi Biotec, Almac House, Church Lane, Bisley, Surrey, GU24 9DR, UK

²The John Goldman Centre for Cellular Therapy, Hammersmith Hospital, Imperial College, Healthcare NHS Trust, Du Cane Road, London, W12 0HS, UK

³Miltenyi Biotec GmbH, Friedrich-Ebert-Straße 68, 51429, Bergisch Gladbach, Germany

⁴The MRC Centre for Regenerative Medicine, The University of Edinburgh, 5 Little France Dr, Edinburgh EH16 4UU, UK

For over 30 years HSC transplantation has remained one of the most efficacious ways to treat Haematological abnormalities such as Leukemia and Lymphoma. Through this time we have learned many lessons along the way. One of the main issues with HSC transplantation is the absence of the Immune system, which increases the risk of virus inactivation. With the ongoing success of cell therapy, recent advances in a process known as Cytokine Capture System (CCS) allows the stimulation and subsequent selection of third party donor virus-specific T cells for transfusion into immunocompromised patients with high viremia. The treatment has shown great efficacy in reducing viral load. However; one bottleneck remains, the lack of time between finding a suitable donor and the manufacture of virus-specific T cells for infusion into patients with an immediate clinical need. To overcome this issue, we at Miltenyi Biotec are in Collaboration with Hammersmith Hospital, London, to ascertain whether virus specific T cells can be manufactured from frozen apheresis. With the aim of creating a cryogenically stored “off the shelf” product that can be used immediately, reducing the delay in treating immunocompromised patients with high viremia. The aim of the talk is to introduce the cytokine capture system, as well as introduce the experimental outline of the project.

1. Feuchtinger, T. et al. (2006) Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. *Br. J. Haematol.* 134: 64–76
2. Feucht, J. et al. (2015) Adoptive T cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. *Blood* 125: 1986–94
3. Peggs, K. S. et al. (2011) Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. *Clinical Infectious Diseases* 52: 49–57
4. Kim, N. et al. (2016) Robust production of cytomegalovirus pp65-specific T cells using a fully automated IFN-γ Cytokine Capture System. *Blood* 128: 5739
5. Moosmann, A. et al. (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. *Blood* 115: 2960–2970
6. Icheva, V. et al. (2013) Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1–specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem cell transplantation. *J. Clin. Oncol.* 31: 39–48

STLB Meeting

Thursday, October 3

Cell shipment without a cold chain

Emma Buick^{1,2}, Jenny Murray¹, Sebastien Farnaud², Derek Renshaw²

¹Life Science Group Ltd

²Coventry University

For transportation, cells are typically shipped in a cryopreserved state, either using liquid nitrogen or dry ice. These methods present a range of logistic challenges, are expensive and often require the use of the cytotoxic cryoprotectant DMSO.

LSG Ltd is working with Coventry University to develop a novel cell shipment medium (CellShip), designed for transporting and storing cells at ambient temperatures. We have identified a defined, xeno free formulation that maintains cell viability over a period of 72 h, including transport by a commercial courier.

HEK293 cells were cultured using complete MEM at 37°C in a humidified 5% CO₂ atmosphere. For transportation, cells were dissociated and pelleted, the culture medium was discarded, and cells were washed once using CellShip. Cells were resuspended in CellShip at $1.4 - 2.3 \times 10^6$ cells per mL in 2 mL aliquots and shipped in cryovials using a commercial courier. Temperatures were monitored using temperature data loggers. Following the 72h transport/storage period, cells were counted and viability assessed, the cells were then recovered in complete MEM at 37°C in a humidified 5% CO₂ atmosphere. Cell numbers and viability were assessed at 24 h and 48 h.

Following the 72h shipment/storage period the mean fold-change in viable cell number was 1.03 (n=4), with a mean cell viability of 98.8%, suggesting that cell number and viability had been maintained. Temperatures recorded ranged from 11°C – 27.4°C, with the maximum range of 13°C in a single experiment. Following 24h recovery, cells showed a fold-change of 1.72, which increased to 2.84 by 48h, indicating that there was no lag in recovery, which is often seen following cryopreservation.

A method for transporting cells at ambient temperatures would simplify the supply chain and provide a cost-effective, xeno-free, non-toxic alternative to cryopreservation, benefitting researchers and the cell-based therapy market.

New cryopreservation technology of hMSCs – first preclinical results using DMSO containing or DMSO-free medium

M. Jandová¹, P. Šponer², D. Vokurková³, P. Bauer⁴, A. Filipová⁵, S. Filip⁶, P. Měřička¹

¹Tissue Bank, University Hospital Hradec Králové, Czech Republic

²Orthopaedic Department, University Hospital Hradec Králové, Czech Republic

³Department of clinical immunology and allergology, University Hospital Hradec Králové, Czech Republic

⁴Bioinova, L.t.d., Prag , Czech Republic

⁵Faculty of Military Medicine of the University of Defence in Hradec Králové, Czech Republic

⁶Department of oncology, University Hospital Hradec Králové, the Czech Republic

BACKGROUND: Development of Advanced Therapy Medicinal Products (ATMPs) based on human mesenchymal stromal/stem cells (hMSCs) has been a worldwide effort leading to new strategies in combating number of pathological conditions. This is reflected by increasing number of clinical trials evaluating cultured MSCs isolated from different sources. HMSCs have a tremendous potential for cellular therapy, regenerative medicine and tissue engineering, it is desirable to cryopreserve and bank them to increase their access and availability. **OBJECTIVE:** This research is a part of the clinical trial aimed on using ATMPs based on hMSCs in patients undergoing repeated total hip replacement. Cryopreservation technologies can help to solve situations when the patient is unable to undergo the operation, but cultivated hMSCs are harvested and prepared for application. The main goal of the research was to optimize the efficient cryopreservation protocol to achieve good specifications for cryopreserved hMSCs. We are also in the initial phase of the testing of new DMSO-free cryopreservation medium Biofreezee, Biochrom AG, Berlin, FRG. **MATERIALS AND METHODS:** To compare characteristics of fresh and frozen hMSCs we used trypan blue exclusion test (cell viability), flow cytometry (cell viability and phenotyping), sterility determining and the clonogenic assay of cell proliferation. **RESULTS:** Cryopreserved hMSCs showed good quality parameters after thawing in comparison with fresh hMSCs suspension. At using DMSO containing medium the viability was up to 90% in all cases. The cell purity determined by flow cytometry was also acceptable. All final products of the ATMP were sterile after thawing. **CONCLUSION:** We cryopreserved hMSCs to develop a new ATMP qualitatively matching the parameters of medicinal product obtained from native (fresh) cells. Our result show that the cryopreservation method described in this study is suitable for the ATMP production while allowing the cells to maintain their phenotypic features and viability at GMP-compliant values.

1. Marquez-Curtis, L., Janowska-Wieczorek, A., McGann L. et al: Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects, *Cryobiology*, 71 (2015) 181–197

2. EudraLex: The Rules Governing Medicinal Products in the European Union, Good Manufacturing Practice, Volume 4, 22.11.2017

3. Freimark D., Sehl C., Weber C. et al.: Systematic parameter optimization of a Me2SO- and serum-free cryopreservation protocol for human mesenchymal stem cells, *Cryobiology*, 63 (2011) 67-75

4. Ren G., Chen X. Dong. F. et al.: Concise review: mesenchymal stem cells and translational medicine: emerging issues, *Stem Cells Transl. Med.* 1 (2012) 51-58

Different aspects of clinical-grade processing of multipotent mesenchymal stromal cells: focusing the therapeutic properties depending on the cell source, hypothermic storage and cryopreservation conditions

Y Petrenko¹, I Vackova¹, O Rogulska², O Tykhvynska², M Chudickova¹, A Petrenko², S Kubinova¹

¹Department of Biomaterials and Biophysical Methods, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic

²Department of Biochemistry, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukrai

The opportunities to apply multipotent mesenchymal stromal cells (MSCs) in clinical practice have brought many challenges associated with the choice of most appropriate cell source, transportation methods and cryopreservation. Here we describe the thorough comparative analysis of therapeutic properties of MSCs derived from different sources, and provide some novel information on the clinical-grade hypothermic storage and cryopreservation approaches.

MSCs were isolated from human bone marrow (BM), adipose tissue (AT) and Wharton's jelly (WJ) in accordance with ethical guidelines and expanded in culture medium, supplemented with human platelet lysate. The immunophenotype of cells, their gene expression and growth factor secretion were evaluated by flow cytometry, qPCR and multiplex assay, respectively. The immunomodulatory properties were assessed in co-culture with peripheral blood mononuclear cells (PBMC). The hypothermic storage of MSCs was performed at 4°C in buffered trehalose solution (BTS) (1). The non-toxic cryopreservation of MSCs was done using sugars pre-treatment approach (2) and cryoprotective solutions, containing sucrose, human plasma and DMSO. The therapeutic activity of cryopreserved cells was assessed on a full-thickness skin wound model in mice.

We found that the growth capacity was higher in WJ-MSC and AT-MSC cultures. On the other hand, BM-MSCs had the best capacity to suppress PBMC proliferation. Depending on the tissue source, the significant differences were found in the expression of PDL1, COX2, BDNF and HGF genes and in the protein level of HGF, NGF and VEGF within cell-derived secretome. The 72 hrs hypothermic storage of MSCs in BTS provided high MSC recovery rates and preservation of their differentiation and immunomodulatory properties. The cryopreservation of cells in human plasma, supplemented with sucrose and 1% DMSO resulted in 73% cell recovery. The cryopreserved MSCs using the cryoprotective medium as vehicle solution improved the healing of full-thickness wounds in mice.

Funding: Czech Science Foundation (17-03765S), Czech Health Research Council (NV19-06-00355).

1. Petrenko Y., et al. (2019) Stem Cells International, Article ID 5909524

2. Petrenko Y., et al. (2014) Cryo letters, 35(3), 239-46

Cryopreservation of ovarian tissue: an emerging technology for female germline preservation of endangered species and autochthone breeds

Christiani A. Amorim¹

¹Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium

Many hundreds of exotic species and domestic animal breeds have been lost over the course of the last few decades. In order to avoid a similar fate to other animals threatened with extinction, it is crucial to develop and apply rescue strategies to ensure their survival for the future. One option as a safeguard measure is the cryopreservation of the ovarian reserve: the primordial follicles. Currently, there are three alternatives to cryopreserve this population of small follicles: (i) whole ovary, (ii) ovarian tissue fragments, or (iii) isolated follicles, using either conventional freezing or vitrification methods. After cryopreservation, the samples can be transplanted or cultured in vitro, aiming to produce fertilizable mature oocytes. In this lecture, we will review the current status of the cryopreservation of the ovarian reserve of domestic mammalian species and non-endangered wild animals as a model for threatened and endangered species and autochthone breeds, and discuss new insights into techniques that can be applied in the future.

Vitrification of human eggs for fertility preservation - hype or hope?

Z Holubcova^{1,2}

¹Masaryk University, Faculty of Medicine, Department of Histology and Embryology, Brno, Czech Republic

²Reprofit International, Clinic of Reproductive Medicine, Brno, Czech Republic

Cryopreservation enables the long-term storage of reproductive cells. The advent of this technique revolutionized the field of assisted reproduction. It not only maximizes the success rate of in vitro fertilization (IVF), facilitates clinical treatment management and makes fertility preservation possible for cancer survivors. While freezing of sperm and preimplantation embryos has become a routine IVF procedure with excellent clinical outcomes, cryopreservation of human oocytes remains problematic. The rationale for disappointing results is a unique nature of female gamete and lack of fundamental research. The major factor underlying the notorious propensity of human oocytes to cryoinjury is instability of meiotic spindle, the fidelity of which is critical for faithful post-fertilization development. We use the combination of polarized light microscopy and fluorescent confocal imaging to study the dynamics of acentrosomal meiotic spindle during the vitrification and thawing procedures in human oocytes donated for research. A better understanding of the behaviour of division machinery in vitrified eggs and the way spindle reconstitutes upon warming will help to optimize the timing of critical IVF procedures. In a broader context, improving our theoretical knowledge of human oocyte cryobiology is pivotal for refinement of current cryopreservation protocols, development of novel approaches to female fertility preservation and down-to-earth consulting of women seeking egg freezing for social reasons.

Human oocytes are ready for ultra-fast vitrification after two minutes of exposure to cryoprotectant solutions

M. Gallardo¹, J. Sáenz², R. Risco³

¹Universidad de Sevilla, Escuela Técnica Superior de Ingeniería. Clínicas Ginemed

²Universidad de Sevilla, Escuela Técnica Superior de Ingeniería

³Centro Nacional de Aceleradores. Universidad de Sevilla, Escuela Técnica Superior de Ingeniería

The standard preparation protocol to ready the oocytes for vitrification takes from 8 to 15 minutes, most of which consists on a long exposure to a non-vitrifying solution (n-VS) to allow for osmotic equilibration.

A reduction in the duration of the protocol is desirable to improve the workflow in the IVF setting and reduce the time of exposure of the oocytes to suboptimal conditions: solutions with high molarity at a low temperature.

We developed in MatLab a simulation of the flux of water and solutes through the plasma membrane of the oocyte using the 2Parameter formalism. The conditions were reproduced in vivo using microvolumes of the solutions, and the volumetric excursions of the oocyte were recorded in an inverted microscope. Ultimately, oocytes were subjected to vitrification with a closed carrier after different preparation protocols.

We compared a standard equilibration protocol (EP) of 10 minutes of exposure to n-VS (7.5% EG, 7.5% Me2SO) followed by 1 minute of exposure to vitrification solution (VS; 15%EG, 15%Me2SO, 0.5M sucrose) with a short dehydration protocol (DP) consisting of 1 minute of exposure to each solution.

The intracellular molarity of the oocyte at the end of both protocols was similar (5.40M in EP vs. 5.37M in DP); oocytes prepared for vitrification with DP showed a lower normalized water content (26.6% EP vs. 17.7% DP). Unfertilized oocytes survived vitrification in high rates after short dehydration protocols (30/30 DP). And 27/27 threepronuclear zygotes prepared for vitrification with DP survived the process and 24/27 resumed mitosis after 24 hours of culture. These results show that the critical intracellular solute concentration necessary for successful vitrification of human oocytes and zygotes at currently attainable cooling and warming rates can be achieved in just two minutes.

1. Kleinhans, F. W. (1998). Membrane permeability modeling: Kedem–Katchalsky vs a two-parameter formalism. *Cryobiology*, 37(4), 271-289.
2. Hunter, J. E., Bernard, A., Fuller, B. J., McGrath, J. J., & Shaw, R. W. (1992). Measurements of the membrane water permeability (Lp) and its temperature dependence (activation energy) in human fresh and failed-to-fertilize oocytes and mouse oocyte. *Cryobiology*, 29(2), 240-249.
3. Paynter, S. J., Cooper, A., Gregory, L., Fuller, B. J., & Shaw, R. W. (1999). Permeability characteristics of human oocytes in the presence of the cryoprotectant dimethylsulphoxide. *Human reproduction*, 14(9), 2338-2342.

Fertilization Rate And Further Embryo Development Of Human Vitrified MII Oocytes Matured In Vitro From GV Stage Oocytes In Medium Supplemented With Insulin Growth Factor-I

T Yurchuk¹, MPetrushko^{1, 2}, V Piniaiev^{1, 2}

¹Institute for Problems of Cryobiology and Cryomedicine, NAS of Ukraine, Kharkiv, Ukraine

²Medical center “ART-clinic of reproductive medicine”, Kharkiv, Ukraine

Approximately 20% of oocytes obtained after controlled ovarian stimulation (COS) can be nuclear immature and be either at the MI or GV stages (1). Due to the lacking number of mature oocytes retrieved from the patients, immature oocytes can increase the total of available oocytes for current or future fertilization. In vitro maturation (IVM) and vitrification of the oocytes also could be used for fertility preservation for those cancer patients where hyperstimulation cannot be applied (2). Thus, studying of in vitro matured vitrified human oocytes has a great value in infertility treatment by assisted reproductive technology. The aim of this study was to evaluate the maturation capacity and fertilization outcomes of in vitro matured human oocytes in medium supplemented with insulin growth factor-1 prior vitrification.

Immature GV stage denuded oocyte were collected after COS and were underwent IVM in presence or absence of IGF-I and cumulus cells, as well afterwards oocytes which reached the metaphase II stage were vitrified by Cryotop method. After warming the gametes were fertilized by ICSI and their fertilization rate and blastocyst formation rate were assessed.

Maturation, fertilization and blastocyst formation rates were (40.3% vs 87.2%), (23.5% vs 82.5%) and (0 % vs 58%) in oocytes cultured with absence or presence of IGF-I and cumulus cells, respectively.

Our findings have shown that IGF-I can improve the oocyte maturation, fertilization rates of in vitro matured GV stage oocytes prior vitrification. Only in the case of the presence of IGF-I and cumulus cells the matured oocytes after vitrification and subsequent fertilization were able to form blastocysts.

1. Mohsenzadeh M (2012) Ital J Anat Embryol. 117, 190-198

2. Combelles CM (2012) Int J Dev Biol. 56, 919–929

Vitrification of human oocytes: the relationship between incubation timing before freezing and after thawing with state of thawed oocytes and utilization effectivity

Olga Teplá¹, Oleg Lunov², Michaela Frolíková³, Simona Jirsová¹, Kateřina Hortová³, Adela Minks⁴, Irena Kratochvílová²

¹First Faculty of Medicine, Charles University, Apolinářská 18, 128 51 Prague 2, Czech Republic

²Institute of Physics of the Czech Academy of Sciences, Na Slovance 2, CZ-182 21, Prague 8, Czech Republic

³BIOCEV, Průmyslová 595, 252 50 Vestec, Czech Republic

⁴ISCARE IVF a.s., Jankovcova 1596,170 00, Prague 7, Czech Republic

Our work aims to determine the impact of incubation time before freezing and after thawing on utilization of vitrified human oocytes. We based our conclusions on a detailed post-thaw microscopic observation of the oocytes with different incubation time before freezing and after thawing and correlation of these results with a detailed analysis of the oocyte condition at the time of utilization. We showed that the oocytes vitrified after 7 h-long incubation post retrieving have significantly higher probability to be successfully utilized than the oocytes incubated for a shorter period. This could be explained by the observation that longer-incubated oocytes had already formed the meiotic spindle and separated chromosomes (i.e. reached the state typical for matured oocytes in metaphase II) at the time of vitrification. Indeed, oocyte freezing before the meiotic spindle assembly only lead to poor utilization efficiency. The results thus demonstrate that freezing the oocytes too early may critically disturb the crucial process of spindle and chromosome post-thaw state.

From the Ocean to the freezer and back

E. Paredes¹, P. Heres¹, R. Rodriguez-Riveiro¹, J. Troncoso¹

¹Vigo University (Spain)

The global production of blue mussel (*Mytilus galloprovincialis*) has a significant role on the marine aquaculture industry; hence it is one of the most cultivated mollusk worldwide (FAO, 2018). However, several hazards affect the culture and the seasonal supply of mussel seed, which sets up an increasing interest on the development of inland seed production without seasonal limitation and safe of global variations. Cryopreservation can provide the stable storage of living resource of mollusk early development stages throughout the year and the possibility of selection of genetic lines according to production issues. Research has normally focused on short term effects on post-thawed cells (1). Here, cryopreservation long term effects were analyzed on cryopreserved mussel larvae and their capacity for competent seed production using two different larval stages and protocols (2).

Mature blue mussels from Galicia (NW Spain) were spawned and cells were incubated to produce Trochophores (18-20h post-fertilization) and 72h-old D-larvae for these long-term experiments where larvae were incubated post-thaw in the lab on a full larval rearing until reaching the juvenile stage. Then those with higher survival rates were settled into culture ropes and moved into a mussel raft for a year-round monitored incubation in the ocean and the obtaining of a second generation (F2). The study of the cryopreservation long term effects is essential to achieve the totally implementation of cryopreservation for Aquaculture and fish management.

1. Paredes, E., Bellas, j., Adams, s.l. (2013) Cryobiology 65, 256-26

2. Heres, P. et al. (2019) Cryobiology 86, 40-46

Cryopreservation of marine resources and its application on aquaculture industry and biodiversity conservation

P. Heres^{1,2}, J. Troncoso^{1,2}, E. Paredesa²

¹Marine Biological Resources Functional Preservation Service, Estación de Ciencias Mariñas de Toralla, Universidade de Vigo, Illa de Toralla, 36331, Coruxo, Vigo, Spain

²Departamento de Ecología y Biología Animal, Facultad de Ciencias del Mar, Universidad de Vigo, Vigo, Spain

Many factors, such as environmental variations, the anthropologic activity, diseases, parasites and the past improper management threaten several marine invertebrate fisheries, some of them play an important role on the economy worldwide and/or have an important value in the ecosystem network. The present research is focused on the development of specific protocols and biobanking biodiversity as a tool for achieving the sustainability of invertebrate fisheries. Cryopreservation is suitable technique for marine conservation. The work carried out in lab consisted on the development of successful cryopreservation protocols for sea urchin species (*Paracentrotus lividus*, *Echinus esculentus*, *Sphaerechinus granularis* and *Echinocardium cordatum*) and two clams of high commercial value *Venerupis corrugata* and *Ruditapes decussatus*. Cryopreservation will help overcome the seasonal limitations that affect the natural production and boost the implementation of biobanking for the aquaculture industry, by providing a reference back-up copy of a family for selective breeding or allowing crossing between different seasons (Paredes et al., 2013). When tackling each species, toxicity tests were carried out to determine the suitable CPA and cryopreservation protocols were developed to study the larval tolerance to freezing. Further research is involved on the study of larval cryopreservation on other two marine mollusks which have high commercial interest: *Pecten maximus* and *Aequipecten opercularis*.

1. Paredes E, Bellas J, Adams SL, (2013) *Cryobiology* 67, 3 274–279

Genetic and epigenetic stability after cryopreservation: is there real concern? Plant cases

M.E. González-Benito¹, C. Martín¹

¹Dpt. of Biotechnology-Plant Biology, E.T.S.I. Agronómica, Alimentaria y de Biosistemas, Universidad Politécnica de Madrid

The development of efficient cryopreservation protocols is essential for cell, tissue or organ long-term storage. Efficiency of protocols should not only consider the recovery rates but also the genetic and epigenetic stability of the recovered cells. Cryopreservation procedures have been generally considered safe and most reports account for the phenotypic and genetic stability of the recovered cells, tissues or organs. In plants, the origin of these variations is usually attributed to the application of in vitro culture techniques during the cryopreservation process rather than to the low temperatures used. However, more attention is recently given to the epigenetic status of DNA. Epigenetic changes modulate gene expression. Nevertheless, there are some evidences that changes occurred during the cryopreservation protocol could have long-term effects. Cases regarding microorganism, animal and plant cells, tissues, organs will be briefly reviewed.

Our group has been working for the last fifteen years on the effect of cryopreservation on genetic and epigenetic stability in plant species. Cryopreservation processes involve exposure to extreme physiological conditions, such as, not only low temperatures, but also low osmotic potential of the media and solutions used, the dehydration to which tissues are subjected to, or the use of potentially toxic and mutagenic substances such as DMSO. Results and conclusions from our studies on plant cryopreservation regarding how different factors can affect genetic and epigenetic stability in plants will be presented.

This work was supported by projects: AGL2010-21989-C02-01 and AGL2015-64899-C2-1/ MINECO-FEDER

Droplet vitrification: a success story for multiple crops, now including coconut.

H. Wilms¹, K. Longin¹, J. Rhee², B. Panis³

¹Kuleuven

²RDA

³Bioversity International

The coconut tree (*Cocos nucifera*) is regarded as one of the most important palms in the world, with a yearly production of more than 59 M tones (1). However, while the production is increasing, its genetic diversity is under threat. The spread of diseases, pests and changing environmental factors endangers the genetic diversity not only in the natural population but also in the collections from the gene banks, since these are affected by the same factors. Coconut gene banks rely heavily on field banks since the coconut is recalcitrant. In the past years research was published on alternative methods of conservation such as cryopreservation of zygotic embryo's, which would offer a safe long-term solution. Yet, these techniques are still not widely used and not applicable to full grown shoots and with the prospect of preserving clonally propagated plants (f.e. by shoot culture or somatic embryogenesis) alternatives should be sought. This is why our research is focusing on the cryopreservation of shoot meristems. The droplet vitrification technique has already proven its value in other tropical crops such as banana and taro and was in this study applied to coconut (2; 3). Meristems were excised from in vitro shoots and exposed to PVS2 at 0°C ranging from 20 to 65 minutes and finally submerged into liquid nitrogen. After thawing, the meristems showed high survival rates around 86%. Subsequent regeneration was 0-20% with many of the shoot tips showing a "hollow" appearance after 2 months. Further experiments are thus needed to achieve higher regeneration rates.

1. Food and Agriculture Organization of the United Nations (2016) FAOSTAT Database. Rome, Italy: FAO. Retrieved May 18, 2019 from: <http://www.fao.org/faostat/en/#data/QC/visualize>
2. Panis B, Piette B, and Swennen R (2005) Plant Sci 168, 45–55
3. Sant R, Panis B, Taylor M & Tyagi A (2007) Plant cell, tissue and organ culture, 92(1), 107-111

New Zealand's *Actinidia* sp. germplasm conservation using cryopreservation

Nadarajan, J¹, Mathew L¹, Pathirana R¹

¹The New Zealand Institute for Plant and Food Research Ltd, Private Bag 11600, Palmerston North 4442, New Zealand

Kiwifruit is New Zealand's most important commercial fruit crop, with an export value of NZ\$1.8 billion in 2018. Plant & Food Research holds one of the larger collections of kiwifruit germplasm outside China. With field germplasm constantly facing threats imposed by biotic and abiotic factors and it is impossible to replace some of New Zealand's unique genotypes, it is critical that we conserve these genetic resources. Ex situ conservation using seed storage and in vitro technologies including cryopreservation provide an alternative to field storage. Kiwifruit seeds have a high (c. 30%) oil content and differential scanning calorimetry thermal analysis revealed that their lipids are in transitional phase (mixture of liquid and solid phase) at -20°C. Hence, we investigated if conventional seed banking at -20°C is optimum for storage of these seeds. For this, we compared seed germination and vigour following 12 months storage at 5, -20 °C and cryopreservation for six species after drying to moisture content around 7% (fresh weight basis). We have also developed cryopreservation techniques for kiwifruit clonal germplasm conservation to complement seed conservation using droplet vitrification method. We have successfully applied this technique for shoot-tips of nine genotypes from five species, with regeneration ranging between 59% and 87%. Development of successful cryopreservation technologies ensures efficient conservation of New Zealand's kiwifruit germplasm for the long term.

1. Food and Agriculture Organization of the United Nations (2016) FAOSTAT Database. Rome, Italy: FAO. Retrieved May 18, 2019 from: <http://www.fao.org/faostat/en/#data/QC/visualize>
2. Panis B, Piette B, and Swennen R (2005) Plant Sci 168, 45–55. (3) Sant R, Panis B, Taylor M & Tyagi A (2007) Plant cell, tissue and organ culture, 92(1), 107-111

An ultracool desert garden

J Gershik¹, S Lahmeyer¹, J Tin¹, J Trager¹, R Folgado¹

¹Botanical Division, The Huntington Library, Art Collections, and Botanical Gardens, 1151 Oxford Road, San Marino, CA 91108, USA

Desert plants, including cacti and succulents, are adapted to arid ecosystems worldwide where they live with minimal rainfall and extreme temperatures. However, a wide range of human activities are the main threats for many wild populations of desert plants, and their conservation in living collections is essential to maintain diversity. The Huntington Desert Garden, more than 100 years old, holds one of the most significant collections of cacti and succulent plants in the world. Nowadays, it displays more than two thousand species belonging to more than two dozen plant families. The Cactaceae, Agavaceae, and Aloaceae families are three of the most representative groups, and they all contain numerous endangered species.

A cryobiotechnology program was created at The Huntington to assure the long-term conservation of the Desert Garden collections. Therefore, we performed seed germination trials for cacti, agaves, and aloes to test their tolerance to liquid nitrogen. Most of the examined seeds showed tolerance to the liquid nitrogen exposure, and a seed bank is being created to maintain wild-collected accessions of threatened species. Although seed preservation is an excellent system to maintain the diversity of these plants, seeds of aloes and agaves are more challenging to obtain. Moreover, the field collections also contain clonal accessions with botanical and historical value. We developed cryopreservation protocols for several clones from different Agave and Aloe species to assure long-term conservation of relevant accessions, using droplet-vitrification based methods. Rooted plants regenerated from rewarmed meristems after liquid nitrogen exposure. Our work is leading to the creation of a germplasm bank that will preserve some relevant accessions from the Desert Garden collections.

Recovery and post-thaw assessment of human umbilical cord blood cryopreserved in quality control segments and bulk sample

Peter Kilbride¹, Julie Meneghel¹, Stephen Lamb¹, John Morris¹, Jerome Pouzet², Christopher Leonforte³, Monika Jurgielewicz³, Daniel Gibson³, Alejandro Madrigal³

¹Asymptote, General Electric Healthcare, Sovereign House, Histon, Cambridge, CB24 9BZ, UK,

²General Electric Healthcare, Biosafe SA, 1 route du petit Eysins, 1262, Eysins, Switzerland,

³Anthony Nolan Cell Therapy Centre, Nottingham Trent University, Clifton Campus, Clifton Lane, Nottingham, NG11 8NS, UK

The cryopreservation of umbilical cord blood and cellular therapies often relies on cryopreserved quality control (QC) segments to assess the state of the bulk sample prior to its thaw. These QC segments are usually cryovials or sealed tubing which are cooled concurrently with the bulk sample, from the same starting material. These are thawed independently of the bulk sample to assess quality of the cryopreserved product. However, there is often variation between the QC segment and the bulk sample on thaw, which can lead to unnecessarily discarded therapies. In this study we have quantified these differences, finding a reduction in total viable cells of approximately 10% in the QC segments. Additionally, we have shown that CD45+ cells are more adversely impacted than CD34+ cells, which changes the population composition post-thaw. The QC segments were found to nucleate at a temperature 9.4°C lower than the bulk sample and this may be the cause of such variation.

In addition, we have explored the impact of different cooling protocols, including and excluding a 'plunge' step, and shown that these give equivalent results to each other, while maintaining the QC segment versus bulk sample differences.

Improving nucleation strategies between bulk samples and QC segments could improve outcomes and accuracy in not only cord blood based therapies, but more widely with other cell therapies.

Assessment of viability of long-term stored cryopreserved allogeneic venous grafts using vital fluorescence dyes and confocal microscopy

Měřička, P.¹, Špaček, M.², Janoušek, L.³, Benda, A.⁴, Sabó, J.⁴, Dalecká, M.⁴, Špunda, R.², Hrubý, J.², Honegrová, B.¹, Gregor, J.¹, Štěrba, L.¹, Lindner, J.²

¹Tissue Bank University Hospital Hradec Králové, Czech Republic

² 2nd Dept. of Surgery-Dept. of Cardiovascular Surgery 1st Medical Faculty Charles University and General University Hospital, Prague, Czech Republic

³ Institute for Clinical and Experimental Medicine, Prague, Czech Republic

⁴ Imaging Methods Core Facility at BIOCEV, operated by Faculty of Science, Charles University, Czech Republic

Aim: To assess viability of cells of allogeneic cryopreserved veins after storage for several years.

Methods: The study was performed in eight great saphenous vein grafts harvested in brain death donors and sent to the Tissue establishment EU TE Code CZ 000427 (TE) in the cooled (+4°C) organ preservation solution (Celsior, Genzyme, The Netherlands). Decontamination in antibiotics according to van Kats (1), and controlled rate freezing in the cryoprotective solution containing 10%DMSO were performed in the TE within 24 hours (2, 3). Storage in the vapour phase of liquid nitrogen for three (2 grafts) and/or five years (six grafts) followed. Grafts selected for the study did not meet the criterion of sterility, other criteria required for clinical application were met. After thawing and removal from the cryoprotective solution the grafts were sent to the Imaging Methods Core Facility in the cooled (+4°C) organ preservation solution (Custodiol CE, Dr. Franz Kohler Chemie, GmbH, FRG). Each graft was divided into three segments, in one of them viability was assessed immediately, the remaining segments were cultured in the CO₂ incubator for 24 and 48 hours in the Dulbecco medium. The tissue slices obtained by perpendicular and longitudinal cutting of vessels and stained with vital dyes according to Johnson and Rabinovitch (4) were examined by confocal microscopy.

Results : Immediately after thawing the mean cell viability in slices obtained by perpendicular cuts (PC) was 81%, SD 6.5, median 87.5%, in slices obtained by longitudinal cuts (LC) the mean viability of 73.5%, SD 4.8, median 76.5% was observed. After 48 hours of culture the mean viability in PC declined to 60.6%, SD 6.8, median 66.5 %, in LC the mean viability of 74.8%, SD 5.9, median 79% was observed.

Conclusion: The results showed good preservation of cell viability after long term storage and good stability of results after short term culture.

1. Van Kats, JP, van Tricht, C., van Dijk, A et al.: Microbiological examination of donated human cardiac tissue in heart valve banking. Eur. J. Cardiothorac. Surg. 37, 2010, p. 163-169

2. Měřička, P., Špaček, M., Janoušek, L. et al.: Cryopreservation of vascular grafts for clinical use : Retrospective analysis of pre-freezing factors with potential impact on the quality and safety of vascular transplantations Cryobiology 71, 2015, p. 546-547

3. Špaček, M., Měřička, P., Janoušek, L. et al: Current vascular allograft procurement, cryopreservation and transplantation technique in the Czech Republic. Advances in Clinical and Experimental Medicine, 28, 2019, p. 529-534

4. Johnson, S, Rabinovitch, P.: Ex vivo imaging of excised tissue using vital dyes and confocal microscopy. Current Protocols in Cytometry, 61, 2012, p 9.39.1-9.39.18

Efficacy of a Novel Precision Dry Thawing System: Preservation of Plasma Anti/Coagulation Proteins Necessary for Use in the Clinic

FZ Bischoff¹, W Davey², F Thacher¹, B Read², T Dileon², R Laba¹, M Shavit¹

1. FreMon Scientific, Inc, San Diego, CA,
2. San Diego Blood Bank, San Diego, CA

BACKGROUND: Fresh frozen plasma (FFP) is an appropriate therapy for supplementing coagulation factors in bleeding requiring massive transfusion. Before transfusion, thawing of FFP is monitored closely to avoid contamination and uncontrolled or prolonged thawing (plasma protein denaturation). Thawing devices must avoid damage to the plasma bags and bacterial contamination while rapidly warming. In this study, we evaluated the effect of a novel precision dry thawing device (ZipThaw) on clinically relevant clotting factor activities.

STUDY: The UCSD School of Medicine testing Lab received a total of 197 freshly collected (pre-freeze) or freshly thawed plasma samples prepared using a standard commercial thawing device and ZipThaw. The Lab conducted over 1,782 tests for the following factors: Prothrombin time (PT), International Normalized Ratios (INR), Activated-Partial-Thromboplastin time (aPTT) Factor VIII activity, Factor V activity, Protein C activity, Protein S antigen, Von Willebrand activity and Thrombin Antithrombin Complex (TAT) concentration. [Carried out on ACL TOP 700 Hemostasis Analyzer using manufacturer's reagents w/ validated precision CV of 5-10% within 4 hours of collection/thawing. Two-tailed, student t-test performed]

RESULTS: 100% concordance between the two thawing methods was observed, with no significant differences between the pre-freeze group and the two post thaw groups, slight increase in the mean TAT complex observed. Overall, the means of all three groups were within the normal range as defined by the assay. Further, the increased mean TAT is more notable with standard thaw method (33%, $p = 0.004$) then with the

ZipThaw (18%, $p = 0.054$).

CONCLUSIONS: We report for the first time non-inferiority between the ZipThaw dry thawing device and the leading commercial thawing device by preserving anti/coagulation proteins and minimizing activation of clotting cascade. The results support potential utility in plasma and cellular therapies requiring the controlled precision thawing.

SLTB Meeting

Friday, October 4

Towards biobanking of tissue-engineered products

O Gryshkov¹, V Mutsenko¹, B Glasmacher¹

¹Institute for Multiphase Processes, Leibniz University Hannover, Germany

The production of tissue-engineered products (TEPs) holds great promise for biomedical applications. Cryopreservation is a strategy of choice to achieve reliable long-term storage of TEPs and their off-the-shelf availability. The goal of this work was to develop an appropriate method for cryopreservation of cell-seeded electrospun scaffolds, mimicking the native tissue. Fibre mats were prepared by blend electrospinning of polycaprolactone and polylactide (100:50). The UV-sterilized scaffolds (thickness $100\pm 10\mu\text{m}$, fibre diameter 0.5-1.0 μm , sample diameter 16mm) were seeded with SaOS-2 cells (1×10^5 cells/scaffold). The following cryopreservation parameters were optimised: 1) pretreatment with sucrose (0.05M, 0.10M, 0.15M), 2) type of cryoprotective agent (10% dimethyl sulfoxide (Me2SO) alone or in combination with 0.3M sucrose) and 3) equilibration with CPA before freezing (10, 30min). The cell-seeded scaffolds were frozen on day 3. After equilibration with CPA, its excess was removed and the samples were frozen in 12-well tissue culture plates using a controlled rate freezer (cooling rate of 1K/min down to -100°C). After storage, the scaffolds were thawed in a 37°C water bath for 1min and recultivated for 24h. The viability of cells was monitored using Calcein AM/EthD-1 as well as Resazurin reduction assay before freezing and within 1 week after thawing. The results showed high viability of cells on scaffolds during culture (95%). The pretreatment with sucrose led to steady decline in cell viability with increasing concentration. Resazurin assay proved that the cells recovered well after thawing. Application of shorter equilibration time, pretreatment with 0.1M sucrose and addition of 0.3M sucrose to Me2SO resulted in the highest cell viability after thawing (70%). Taken together, this work provides next steps towards efficient cryopreservation and biobanking of TEPs.

A Meta-analysis of the Boyle van't Hoff Relation and New Developments in Osmotic Regulation Modeling

D Olver¹, J Benson¹

¹University of Saskatchewan

The relationship between extracellular concentration and equilibrium cell volume is critical for mathematical modeling of cryopreservation protocols. The current paradigm is to use the linear Boyle van't Hoff relation (BvH) to predict cell size relative to external concentration. The BvH model assumes no regulatory volume decrease/decrease of the cell or hydrostatic pressure (turgor pressure) exerted by the cell membrane. However, it is well known that some cells exhibit regulatory volume control and others withstand significant transmembrane pressure gradients. Therefore, to verify if the BvH model is an appropriate for cells in general, we compiled 139 BvH data sets from 1964 until July 2019. We performed a Durbin Watson [DW] autocorrelation test and determined that the BvH model is highly autocorrelated (DW score $0.961 < 1.781\text{crit}[dL]$). Additionally, we found that the BvH model may be appropriate in the hypertonic region (DW score $1.855 > 1.700\text{crit}[dU]$). Because of this apparent insufficiency in the linear BvH model, we developed a new model that considers hydrostatic pressure (turgor pressure) as a mechanism to produce a nonlinear response. This model predicts the BvH relation to hold until some turgor point, after which the volume - inverse osmolality relation becomes non-linear according to the plane stress of the cell. This turgor model is found to work well as a general model, resulting in unautocorrelated best-fit residuals (DW score $2.02 > 1.790\text{crit}[dU]$). We conclude that the BvH relation is inappropriate for cells unless experimentally validated and may only be appropriate for a specific osmotic region. Our model predicts cryoprotectant loading and unloading protocols are not optimized since they do not account for this effect.

Post cryopreservation delayed cell death in hepatic organoids is linked to cell-matrix interactions

Maooz Awan¹, Eloy Erro¹, Barry Fuller², Clare Selden¹

¹UCL Institute for Liver and Digestive Health, UCL Royal Free Hospital Campus, UCL Medical School, London, NW3 2PF, United Kingdom

²Dept. of Surgery, UCL Medical School, Royal Free Hospital, London, NW3 2QG, United Kingdom

Effective cryopreservation of organoids requires an understanding of the cell-extracellular matrix (ECM) interactions during freezing. The Bioartificial Liver Machine (BAL) is a tissue engineered extracorporeal organ support. The BAL biomass consists of alginate encapsulated liver spheroids (AELS). Successful cryopreservation of the BAL biomass is essential to its success as a tissue-engineered product. The liver spheroids produce their own ECM and have upregulated hepatic function compared to monolayer.

Focal Adhesion Kinases (FAKs) are a type of non-receptor tyrosine kinase involved in cell-ECM interactions; in normal cells these interactions are vital for cell growth, function and survival.

Alginate encapsulated liver spheroids (AELS) were grown in a fluidised bed bioreactor for 12 days until spheroid formation was achieved and cryopreserved by slow cooling (0.3°C/min) using 12% DMSO. Warming (about 9°C/min) was followed by washing to remove the CPS. AELS were then returned to culture for 48 hours. The formation of FAKs before and after cryopreservation of AELS was assessed by immunofluorescence. The FAKs were stained with an anti-vinculin antibody, spheroids were co-stained for actin (phalloidin) and nuclei (Hoechst) and imaged using a confocal microscope. Viable cell number was determined by nuclei quantification and live/dead staining.

The number of FAKs fell during the first 24 hours post-thaw. The spheroids were no longer anchored to the matrix. This detachment was accompanied by a 30% decrease in the viable cell number at 24 hours (n=3). These FAKs re-established themselves after 48 hours, accompanied by recovery of viable cell number (n=3).

These results link post cryopreservation cell death to detachment, commonly known as anoikis. Scaling up of cryopreservation protocols from cell suspensions to organoids, and eventually whole organs must consider how the essential cell-ECM interactions will be preserved.

Computational modelling and optimisation of cryopreservation protocols using BioDynaMo

Jack L Jennings¹, Lukas Breitwieser², Sanja Bojic^{1,3}, Roman Bauer^{1,3}

¹School of Computing, Newcastle University, Newcastle upon Tyne, UK

²CERN openlab, CERN, Geneva, Switzerland

³Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

Cryopreservation of biological tissue is currently in its infancy. Approximately 2/3 of donated hearts and lungs cannot be transplanted, mainly due to lack of suitable preservation capabilities. Moreover, the synthetic growth of tissues for clinical purposes, as well as large-scale pharmaceutical testing would benefit from progress in cryopreservation. Cryobiologist Peter Mazur has pioneered the theoretical/mathematical modelling of cell freezing (1,2). However, due to the complexity of the problem, the field still lacks a well-established computational component and so relies mainly on a trial-and-error approach.

The advances in computing technology have rendered it possible to incorporate highly detailed and large-scale models of biological tissues. Here, we present CryoDynaMo, an agent-based computational software for the modelling and simulation of slow-freezing of biological tissues. CryoDynaMo is an extension of BioDynaMo (3,4), an open-source software platform for computer simulations of biological tissue dynamics. Along those lines, we demonstrate that CryoDynaMo can account for experimental findings using various cryopreservation protocols, in particular involving different cooling rates. Moreover, we present preliminary results of tissue viability, taking into account recent experimental results from murine neuroretina. Overall, CryoDynaMo constitutes a computational framework that allows to incorporate experimental data and optimise cryopreservation protocols.

1. Mazur P (1970) Science 168, 939-949.

2. Mazur P (1984) Am J Physiol Cell Physiol 247, C125-C142.

3. Bauer R, Breitwieser L, Di Meglio A et al. (2017) in Advanced Research on Biologically Inspired Cognitive Architectures, (eds) IGI Global, pp. 117-125.

4. <https://biodynomo.web.cern.ch/>

Improving sample identification and reducing risks during cryostorage of vitrified gametes and embryos using radio frequency identification (RFID) tags that operate while samples are immersed in liquid nitrogen

Palmer GA¹, Parker PA², Dawson- Smith KJ², Igbokwe, NN³

¹London Women's Clinic Wales, 15 Windsor Place, Cardiff, UK

²Kustodian Ltd, Harben House, Harben Parade, Finchley Road, London, UK

³Watford General Hospital, Watford, Vicarage Road, Watford, Hertfordshire, UK

Until recently, no radio frequency identification (RFID) label could operate reliably at low temperature suitable for prolonged gamete and embryo storage in liquid nitrogen. Here we describe a unique identification and audit system that can monitor the quantity and position of individual frozen samples stored in liquid nitrogen inside a Dewar. The system is in principal adaptable to any Dewar size and brand. While established methods of cryopreservation have been documented since the 1950s for semen (1) and 1984 for human embryos (2), in the last decade, vitrification has progressively become the method of choice for the cryopreservation of human oocytes and embryos owing to improved post thaw survival and pregnancy outcome (3).

Recent publications, however, predicting the effects of sub-optimum conditions for vitrified samples (4) during sample audits have raised concerns about operating procedures. In the UK it is mandatory for a 2nd person to verify all processes involving transfer of gametes or embryos and good practice dictates periodic audits which further involve removing samples from their immersed state (5).

Existing auditing methods are laborious, time consuming and serious shortcomings of interpreting standard labelling have been extensively addressed (6). RFID labelling and functionality in liquid nitrogen conditions would offer heightened security, safety and uninterrupted traceability.

We demonstrate here that in 56 test cycles, correct location of all frozen samples can be reported within a modified Dewar by a simple operation imitating a tank audit. Moreover, in a further 96 blind studies a "misplaced sample" could be allocated instantaneously. Similarly. notification of the absence of a documented sample (missing sample) had been recorded in 100% of the trials (n=44). We demonstrate the proof of concept in using specialized RFID tags in an industry finally coming to terms with a heightened awareness of risk assessment (7).

1. Anger TS, Gilbert BR & Goldstein M (2003) The Journal of Urology 170 (4 Pt 1):1079-84

2. Zeilmaker GH et al (1984) Fertil Steril. 42, 293–296

3. Edgar DH & Gook DA (2012) Hum. Reprod. Update 18, 536–54

4. Sansinena M et al (2018) Reprod Biomed Online. 36(5), 500-507

5. Human Fertilization and Embryology Authority (HFEA) Code of Practice, 9th Edition (2019) <https://www.hfea.gov.uk/media/2793/2019-01-03-code-of-practice-9th-edition-v2.pdf>

6. Tomlinson M (2005) Hum. Reprod., 20(7), 1751–1756

7. Alikani M (2018) Reprod. Biomed. Online. 37, 1-3

Thermal analysis methods as a tool for development of cryopreservation protocols

Miloš Faltus¹, Stacy Hammond Hammond¹, Jiří Zámečník¹

¹Crop Research Institute, Drnovska 507, Prague 6, CZ16106, Czech Republic

Understanding the behaviour of the water content in plant tissues during cooling and heating is a key factor in developing a reliable cryopreservation protocol as high water content during these processes can result in sample injury (Zámečník, Faltus, 2011). Differential Scanning Calorimetry (DSC) thermal analysis methods such as standard DSC (DSC), Temperature Modulated DSC (TMDSC) and Quasi-isothermal Temperature Modulated DSC (QITMDSC) represent a viable tool that can improve the knowledge of the thermal events (Zámečník, Faltus, 2014) and so help to reduce ice crystallization and cell damage by frost and so contribute in the development of more efficient and reliable cryopreservation protocols (Volk, Walters, 2006). The standard DSC was used for routine measurement when dealing with samples with known thermal properties and non-overlapping thermal events. Amount of freezable water or glass transition were detected by the standard DSC after specific sample dehydration. MDSC method was used for analysing samples with overlapping thermal events. The method helped to separate a total heat-flow signal into thermodynamic and kinetic events. QITMDSC method was used for the exact measurement of heat capacity in equilibrated conditions, that help to identify the sample state of matter. Here we intend to demonstrate how the use of these DSC thermal analysis methods can be applied in the development of cryopreservation protocols, what DSC methods are appropriate for samples with specific thermal characteristics, what thermal events can endanger sample cryopreservation stability, and what results can be expected using a specific thermal analysis method.

This study was supported by research projects of the Ministry of Agriculture of the Czech Republic QK1910277 and MZE RO0418.

1. Volk, G. M., Walters, C. (2006). Plant vitrification solution 2 lowers water content and alters freezing behavior in shoot tips during cryoprotection. *Cryobiology*, 52(1), 48-61
2. Zámečník, J., Faltus, M. (2014) Physiological and Biophysical Responses of Plants under Low and Ultralow Temperatures. In: Pessarakli, M. (ed.). *Handbook of Plant and Crop Physiology*. CRC Press, Boca Raton, Florida, USA, pp. 557-584
3. Zámečník, J., Faltus, M. (2011) Behavior of Water in Plants at Low and Ultralow Temperatures. In: Pessarakli, M. (ed.). *Handbook of Plant and Crop Stress*. CRC Press, United States of America, pp. 288-313

The cryoprotectant DMSO. Identifying problems and developing its safe and effective use

I Buriak¹, R Fleck², B Fuller³, G Stacey⁴

¹Department of Cryomicrobiology, Institute for problems of cryobiology and cryomedicine, National Academy of Sciences of Ukraine, Kharkiv, Ukraine

²Centre for Ultrastructural Imaging, Kings College London, London , UK

³Department of Surgery, Royal Free Hospital, UCL, London , UK

⁴International Stem Cell Banking Initiative, Barley, Hertfordshire, UK

DMSO has long been the cryoprotectant of choice for cell and tissue cryopreservation. It is extensively used for cryopreservation of haemopoietic progenitor cells, bone marrow and others. DMSO has also been employed in medicine and veterinary applications as an anti-inflammatory drug. It is also used to enhance the penetration of therapeutic agents through cell membranes. However, despite its many benefits, DMSO toxicity and adverse reactions remain a topic of debate.

The aim of our study was to review the biological effects of DMSO and its toxicity with context to its effectiveness and value in the cryopreservation of transplants for cell therapy.

DMSO has a wide range of biological effects determined by its chemical nature. The effects of DMSO depend on its concentration, exposure time and cell type. DMSO is able to increase cell membrane fluidity. Membrane perturbations result in changes of cytosolic Ca²⁺ levels, function of Ca-dependent enzymes and translocation of specific messengers involved in cell differentiation. Impairment of mitochondrial membrane potential and inhibition of respiration have been also reported. DMSO can act as an apoptosis trigger. DMSO affects genomic processes in cells not only via specific messengers but also by changing DNA methylation profiles, up- or down-regulating different genes. DMSO has been reported to cause adverse reactions in patients after transplantation of cryopreserved cells

The methods of minimizing DMSO adverse effects and cellular toxicity are reduction of overall DMSO concentration, its removal or depletion before transplantation and replacement of DMSO with alternative cryoprotectants.

As with most drugs, DMSO can cause either positive or negative outcomes. To avoid possible adverse results of DMSO application as a cryoprotectant an understanding of its biological impact is required. These will be discussed as will further studies and the importance of the development of novel approaches to cryopreservation of cell grafts.

Fibroblast cryopreservation in nanocrystalline cerium dioxide containing media

O Polivanova¹, O Falko², O Sidorenko², V Chizhevsky²

¹PhD student, IPC&C NAS of Ukraine

²PhD, IPC&C NAS of Ukraine

The actual cryobiological issue is cryopreservation protocols improvement to increase the quality of preserved material. A solution to the problem may be found in a toxic cryoprotectant (DMSO) (1) concentration decrease and use of effective protective components such as nanocrystalline cerium dioxide (NCD). It is known that NCD has explicit antioxidant properties, which are quite valuable for cryobiotechnologies (2, 3).

The mice fibroblasts of L929 cell line were cryopreserved in the media containing 1% and 5% DMSO and NCD in concentration 1 g/l (experimental samples). The samples containing 1%, 5% and 10% DMSO were used as a control. Cell number in each sample was 1 million/ml, the sample volume was 1 ml. All samples were frozen with the rate 1 degree/min to down -40C with further immersion into liquid nitrogen.

To assess the cryopreserved fibroblasts viability the fluorescent marker 7-aminoactinomycin D (7-AAD) was used.

In control samples the number of 7-AAD positive cells was 73.02±1.20%, 52.11±2.03% and 15.09±3.40% respectively, in experimental samples it was 46.05±1.36% and 49.07±1.14% respectively.

Thus, fibroblasts cryopreservation with DMSO of low concentration is possible if NCD is used as a protectant component. The findings need to be comprehensively investigated in future.

1. Fry LJ et al (2015) For Vox Sang. Vol 109, 181–190
2. Makashova OE et al (2016) Probl Cryobiol Cryomed Vol 26, 295–307
3. Scherbakov AB et al (2011) Biotechnol. Acta. 4, 9–28

New cryoprotectants based on Natural Deep Eutectic Solvents

Ana Rita Jesus¹, Ana Rita C. Duarte, Alexandre Paiva

¹Faculdade de Ciências e Tecnologia, NOVA University

Deep Eutectic Solvents (DES) are a new class of solvents that have emerged in the last decade and can be described as a result of intermolecular hydrogen bonds between two or more compounds that at a specific and adequate molar ratio cause a strong depression in the melting point when compared to those of the individual components¹. When such components are natural primary metabolites such as sugars, sugar alcohols, amines, and amino acids, DES are called Natural Deep Eutectic Solvents (NADES). These metabolites can be found in animals living in extreme cold environments and are involved in the hibernation process allowing them to survive during winter time^{2,3}.

This work aimed the use of NADES composed by these natural primary metabolites as cryoprotectants, as an alternative to DMSO.

The successful production of these eutectic systems was confirmed by polarized optical microscopy (POM), showing the existence of an amorphous material. Moreover, Nuclear Magnetic Resonance (NMR) data confirmed the strong interactions between the components of each NADES system through hydrogen bonds.

Furthermore, cytotoxicity was evaluated and IC₅₀ of NADES determined in mammalian cells, with values ranging from 1.0-2.2 M. Differential Calorimetry Scanning (DSC) technique was also used to evaluate the thermal behaviour of these eutectic systems, showing the strong effect on the water crystallization/freezing and melting processes which proves that these NADES are able to reduce the formation of ice crystals. The work herein presented opens new possibilities in cryopreservation and broadens the spectra of cryoprotective agents suitable for cell storage under cryogenic temperatures, reducing the cell damage and improving cell survival after thawing.

1. Yang Liu, J. Brent Friesen, James B. McAlpine, David C. Lankin, Shao-Nong Chen, Guido F. Pauli, *Journal Natural Products*, 81 (2018) 679–690

2. Ana Gertrudes, Rita Craveiro, Zahara Eltayari, Rui L. Reis, Alexandre Paiva, Ana Rita C. Duarte, *ACS Sustainable Chemistry Eng.ineering*, 5 (2017) 9542–9553

3. Vânia I.B. Castro, Rita Craveiro, Joana M. Silva, Rui L. Reis, Alexandre Paiva, Ana Rita C. Duarte, *Cryobiology*, 83 (2018) 15-26

Fructose oligosaccharides as a novel cryoprotectant for mammalian cells

P Kilbride¹, A Hugo², J Meneghel¹, J Delettre³, N Romano², JG Morris¹, A Gomez-Zavaglia², S Passot³, F Fonseca³

¹Asymptote, General Electric Healthcare, Sovereign House, Histon, Cambridge, CB24 9BZ, UK,

²CIDCA, Center for Research and Development in Food Cryotechnology, Calle 47, Casco Urbano, B1900AJJ, La Plata, Buenos Aires, Argentina

³UMR GMPA, AgroParisTech, INRA, Université Paris-Saclay, Thiverval-Grignon, 78850, France

Successful cryopreservation of mammalian somatic cells requires the use of cryoprotectants, among which dimethyl sulphoxide (Me2SO) remains the most common. The cryoprotective abilities of Me2SO were first recognized 60 years ago (1). However, Me2SO presents a cytotoxicity risk to cells, requiring precise and careful use: it must be added to cell suspensions under chilled conditions, washed out or diluted post-thaw. The long-standing demand to develop new cryoprotectants which may be used instead of or in conjunction with lower doses of DMSO remains unanswered.

Fructose-based oligosaccharides (FOS), demonstrating cryo- and lyo-protective abilities on bacterial cells (2), appear as a potential alternative to Me2SO for the cryopreservation of mammalian cells. In this study, we have examined the use of FOS solutions as cryoprotectants in a range of mammalian somatic cell types. Cryoprotection by FOS was observed with Chinese Hamster Ovarian cells, Jurkat (immortalized T cell line), and CACO-2 (colorectal adherent) cells, with cell membrane integrity, Alamar blue functionality, and proliferation of the cells observed. Disparate cell types were specifically chosen to determine if FOS could be used more generally as a mammalian somatic cryoprotectant and was not cell specific. The optimal concentration and composition of FOS solutions were determined. To better understand their cryoprotective mechanisms, the relationship between the degree of cryoprotection and some physical properties of the FOS solutions (nucleation temperature, glass transition temperature, osmolarity, viscosity) was also investigated.

This work forms the basis of using FOS as a cryoprotectant for mammalian cells, and this group of sugars may prove a novel source for mammalian somatic cell cryopreservation.

This project has received funding from the European Union's Horizon 2020 Marie Skłodowska-Curie research and innovation programme under grant agreement N° 777657.

1. Lovelock JE & Bishop MW (1959) *Nature* 16;183(4672):1394-5

2. Romano N, Schebor C, Mobili P et al (2016) *Food Res. Int.* 90, 251-8

Critical defects in cryopreserved cell nuclei: DNA structure changes

Martin Falk¹, Daniel Šimek², Martin Golan², Krisztina Varga³, Olga Teplá⁴, Irena Kratochvílová²

¹The Czech Academy of Sciences, Institute of Biophysics, Královopolská 135, CZ-612 65 Brno, Czech Republic

²The Czech Academy of Sciences, Institute of Physics, Na Slovance 2, CZ-182 21, Prague 8, Czech Republic

³Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, 46 College Road, Durham, NH 03824, USA

⁴VFN Gynekologicko-porodnická klinika, Apolinářská 18, CZ-120 00, Czech Republic

Cryopreservation of cells is a fundamental task for a wide range of applications. First in this work, a detailed description of cryopreserved cell nuclei was connected with selected cryoprotectant effectiveness. We simultaneously evaluated changes in DNA, chromatin higher-order structure, and nuclear envelope of untreated or cryopreserved frozen cells. To determine the importance of subcellular changes and freezing mechanism on cell survival upon freezing/thawing, we treated the cells with different types of cryoprotectants: dimethyl sulfoxide, trehalose and ApAFP752 antifreeze protein. Beside nuclear envelope quality, we identified chromatin condensation as an important factor that strongly manages cryopreserved cell survival. Different cryoprotective compounds induced chromatin condensation to a different extent, corresponding to their effectiveness. We simultaneously evaluated DNA defects and the higher-order chromatin structure of frozen and thawed cells with and without cryoprotectant treatment. We found that in replicating (S phase) cells, DNA was preferentially damaged by replication fork collapse, potentially leading to DNA double strand breaks (DSBs), which represent an important source of both genome instability and defects in epigenome maintenance. Results of our work bring deeper understanding of the freezing processes, especially their effects on cell nuclei, and will contribute to the rational design of cryofunctional compounds and applications.

The pharmaco-physiology of surviving hypothermia in the organ transplant pathway

Barry Fuller¹, Farid Froghi¹, Brian Davidson¹

¹Dept. of Surgical Biotechnology , UCL Division of Surgery & Interventional Science, Royal Free Hospital Campus, London, NW3 2QG, United Kingdom

The start of organ transplantation in the 1960's identified a crucial need to be able to preserve organs outside the body for several hours, and cooling to hypothermic temperatures became the method of choice. Cooling reduced ischaemic injury to some degree, but introduced other biochemical challenges for the cells which needed to be mitigated in order to be able to reliably transplant a functioning graft. The outcomes of rewarming the organs could produce additional injury by what became known as Ischaemia / reperfusion injury. Physiologists and cryobiologists worked to control these injury processes by providing special solutions via organ flushing to reach the internal cellular components – and the science of organ preservation was born. The current talk will review the historical development of organ preservation solutions, and the increasing understanding of I/R injury over the past decades. This will be put in the context of organ sharing logistics as they have developed into the sophisticated clinical services of the 2010's. The move towards dynamic hypothermic perfusion in the past decade will be highlighted in relation to the organ preservation solution perspective, and new formulations of organ preservation solutions will be described. Lastly, other novel approaches to cold non-freezing organ preservation solution will be highlighted, and what this may mean for further developments of organ preservation solutions.

An "Off The Shelf" Cryopreservable Regenerative Medicine Cell Therapy (cATMP) For Treating Patients With Liver Failure - UCL BioArtificial Liver Machine

Clare Selden¹, Eloy Erro¹, Sherri Chalmers¹, Maooz Awan¹, Tom Brookshaw¹, Barry Fuller²

¹UCL Institute for Liver and Digestive Health, UCL – Royal Free Hospital Campus, UCL Medical School, London, NW3 2PF, United Kingdom

²Dept. of Surgery, UCL Medical School, Royal Free Hospital, London, NW3 2QG, United Kingdom

Over 1 million people die yearly from liver failure globally. 90% patients do not get a transplant with 25% death on waiting list for Acute Liver Failure patients. Given time, the liver can regenerate and repair itself. Currently there is no effective means to “buy” that time. We developed a cryopreservable BioArtificial Liver machine (BAL), to treat patients with severe liver failure. The BAL, a truly regenerative medicine, is a cell therapy that provides a cell biomass as organoids which delivers liver function temporarily to patients whilst their own liver repairs. It was successfully tested in large animal trials in porcine acute liver failure (ALF).

The logistics of delivery of any regenerative medicine or cell therapy are key to its commercial success. In terms of cell therapies, and particularly in those whose disease target has rapid and severe onset, the ability to cryopreserve the product at clinical scale is of utmost importance.

The in-vivo data we present illustrates the range of functional improvements demonstrated when testing the BAL, such that coagulation function was improved, intracranial pressure diminished, vasopressor requirement markedly reduced, and acidosis corrected.

Mechanisms that impact on cell recovery after cryopreservation have been explored, with respect to recovery of viable cell number. Presenting data on large scale cryopreservation of cell organoids, using >1 litre volumes, we have developed cryopreservation protocols which lead to good recovery of function, indicating the logistics would be suitable for GMP manufacture and clinical use. Successful cryopreservation has been undertaken at volumes higher than any previously reported as far as we know.

In conclusion, using a regenerative medicine cell therapy approach to treat patients with acute, and acute decompensation of chronic liver failure, will reduce the need for organ transplantation in many patients, and enable better use of scarce donor organs.

Cells surviving the ice age

Birgit Glasmacher¹, Vitalii Mutsenko¹, Tim Rittinghaus¹, Damijan Miklavčič¹, Oleksandr Gryshkov¹

¹Institute for Multiphase Processes, Leibniz University Hannover, Hannover, Germany

In nature, a number of species can survive sub-zero temperatures while returning their functionality back to their physiological state at normal conditions. This property results from nontrivial and complex physical-chemical processes taking place in the organism and helping them to survive the ice age. In this key-note lecture I will discuss and give comprehensive information about the following topics related to tissue engineered constructs:

1. Is dimethyl sulfoxide safe enough for freezing of cells and cellular structures?
2. Is electroporation an efficient approach for delivery of sugars into the cells? How it can be applied to cryopreservation of tissue-engineered constructs?
3. Do the most commonly used controlled-rate freezers maintain the set cooling rates?
4. Is controlled ice nucleation superior for stem cells to survive the cryopreservation process more efficiently?
5. What are the most relevant methods to cryopreserve tissue-engineered constructs?

To facilitate cells and cellular constructs to survive low temperature storage it is important to consider a number of processes, which can only be understood combining the knowledge of different fields of science such as engineering, physics, biology, mathematics, and chemistry. Moreover, we do not forget achievements of our passed away pioneers in the field of cryobiology: Peter Mazur, David Pegg and Igor Katkov. With the ideas and achievements of the founding fathers of the science of modern cryobiology we are approaching a new era and thus are not afraid to tackle new and still existing problems in cryobiology.

1. A. Chatterjee, D. Saha, H. Niemann, O. Gryshkov, B. Glasmacher, N. Hofmann. Effects of cryopreservation on the epigenetic profile of cells. *Cryobiology* 2017;74: 1-7
2. L. Lauterboeck, O. Gryshkov, N. Hofmann, B. Glasmacher. Importance of controlled ice formation for efficient biobanking. *Refrigeration Science and Technology* 2016;F126957: 84-90. doi: 10.18462/iir.cals.2016.0007
3. V. Mutsenko, O. Gryshkov, B. Sydykov, A. Beck, D. Dipresa, A. Lode, T. El Khassawna, A. Petrenko, S. Korossis, W.F Wolkers, M. Gelinsky, B. Glasmacher. 'In air' cryopreservation of mesenchymal stromal cells on 3D collagen-hydroxyapatite-scaffolds. *Cryobiology* 2018;85: 145
4. T. Rittinghaus, B. Glasmacher. Frosty matters: do freezing containers and smart freezers make the grade? *Int J Artif Organs* 2019;42(8): 398-399
5. M. Čemažar, Effects of Electroporation of Mammalian Cells on Cytoskeleton and Intercellular Connections, in: D. Miklavčič (Ed.), Handbook of Electroporation. *Springer*, Cham, 2017: 307–321
6. L.P. Fong, C.J. Hunt, D.E. Pegg. Cryopreservation of the rabbit cornea: freezing with dimethyl sulphoxide in air or in medium. *Curr Eye Res.* 1987;6(4): 569–77

Freezing levels determine successful cryoablation of Ehrlich carcinoma cells

Goltsev A.M.¹, Bondarovych M.O.¹, Babenko N.M.¹, Gaevska Yu.O.¹, Ostankov M.V.¹

¹Institute for Problems of Cryobiology & Cryomedicine of the National Academy of Sciences of Ukraine

During cryoablation in the center and on the periphery of tumor, a significant temperature gradient is observed. The tumor cells are exposed to different temperatures, which may cause incomplete tumor destruction. The research aim was to determine the intensity of necrotic/apoptotic processes and subpopulation composition of Ehrlich carcinoma (EC) after cooling down to different temperatures. The research object was EC cells, as a model of breast cancer, which were grown for 7 days in Balb/C mice peritoneal cavity. The EC cells were frozen in ascitic fluid at a rate of 10 deg/min down to -30°, -60°, -80° C, followed by warming in a water bath at 41°C. After thawing, the number of nucleated cell, their viability, and necrotic/apoptotic cells were determined using Annexin-V (BD, USA) and PI (Sigma, USA); subpopulation composition was examined using monoclonal antibodies (BD, USA) to CD44, CD24 structures. The positive controls were the indices of native EC cells, while the negative ones were those subjected to a direct immersion into liquid nitrogen.

Minimal cell viability ($16.2 \pm 0.7\%$) was observed when the sample reached -80°C, that was almost comparable to 90% cell death in negative control. In all the evaluated variants, the predominant way of cell death was necrosis, with the exception of freezing down to -30°C, whereat the number of cells in apoptosis increased significantly versus all the variants of freezing and controls.

The content of the CD44+CD24-, CD44+CD24+, CD44-CD24+ subpopulations significantly decreased with a reduction in end freezing temperature, while the least differentiated CD44hi were more resistant to low temperatures. The findings indicate among all the tested options, the cooling down to -80°C caused the maximum destruction of tumor cells.

Myometrial function and viability following controlled-rate cryopreservation of ovine uteri

Sabrina Jaffer¹, Matthew Elmes², Juan Hernandez-Medrano¹

¹Department of Obstetrics and Gynaecology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom

²Division of Nutritional Sciences, School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom

Uterine cryopreservation maintains viability and function, and represents a long-term storage option for transplantation (1,2). However, it exhibited decreased myometrial contractile function compared to fresh controls. Here we investigate the effect of slow-freezing cryopreservation (SF) on uterine contractile function in response to increasing oxytocin (OT) concentrations.

Uterine-horns were perfused (0.5ml/min) with cold heparinised-solution followed by CPA (0.1M sucrose, 1.5M Me2SO, 10% FBS in Leibovitz-L15) for 60 (SF60, n=4) or 75min (SF75, n=4) and cryopreserved using a controlled-rate freezer (Planer Ltd). Fresh uterine horns served as controls (CT; n=4). Non-caruncular tissue strips (0.5cm x 1cm) were dissected, mounted and kept in 25ml-organ baths with KH buffer (37°C) and gassed with 95% O₂ / 5% CO₂. Baseline tension and contraction frequency (peaks/min) and force (AUC) were recorded before and after OT cumulative doses (0-9.5ng/ml)(3). Lactate dehydrogenase release (LDH; Roche) and connexin-43 (Cx43; Abcam) were used to evaluate tissue viability. Contractility data (LabChart v6) was analysed using ANOVA for repeated measures, while LDH and Cx43 compared using one-way ANOVA and Kruskal-Wallis tests, respectively.

Spontaneous ex vivo myometrial contractions were evident in CT but not in SF (P<0.05). OT increased frequency (P<0.05) and force (P<0.05) in CT with no response elicited in SFs. Conversely, OT increased basal tension in all tissues (P<0.05) but to a larger extent in CT (P<0.05). LDH release was higher in SF than CT (P<0.05), while Cx43 was lower in SF than CT (P<0.1).

In conclusion, cryopreservation decreases uterine function. This may result from increased tissue (LDH) and/or cellular damage (decrease Cx43) caused by cryopreservation or perfusion. New strategies to reduced damage and improve cryopreservation outcomes will be developed.

1. Brännström M, et al. 2012. Uterus transplantation: animal research and human possibilities. *Fertility and Sterility*. 2012; 97:1269-1276.
2. Dittrich R, et al. 2010. Uterus cryopreservation in the sheep: one step closer to uterus transplantation. *In Vivo*. 24:629-634.
3. Elmes M, et al. 2015. Maternal age effects on myometrial expression of contractile proteins, uterine gene expression, and contractile activity during labor in the rat. *Physiol. Rep.* 3:1–23.

Design of a biological cryoprotector based on on antifreeze proteins linked to a protein transfection domain

Ramon Risco^{1,2} and Juan Vargas-Mancilla^{1,3}

¹Departamento de Física Aplicada III, Escuela Técnica Superior de Ingeniería, Universidad de Sevilla, Spain

²Centro Nacional de Aceleradores (Universidad de Sevilla-CSIC-Junta de Andalucía), Sevilla, Spain

³Instituto Mexicano del Seguro Social, Centro Médico Nacional del Bajío, UMAE HGP 48, León GTO, México

This work addresses the problem of the cryopreservation of cells, tissues and organs in a novel way, avoiding the formation of ice in the cytoplasmic and interstitial space of tissues and organs by means of the internalisation of the protein AFPIII-Penetratin.

We carried out the molecular strategy to build the recombinant protein based on AFP type III antifreeze proteins linked to a protein transfection domains named penetratin. Then we constructed, expressed and tested the effectiveness of the recombinant protein AFPIII-Penetratin, performed different experiments to determine the viability of the protein such as differential calorimetry, assessed its penetration capacity in cells, tissues and organs by immunocytochemistry and confocal microscopy, and determined the cryoprotectant capacity of AFPIII-Penetratin at different subzero temperatures in cell lines, tissues and organs.

Acknowledgments: Dr. Rafael Fernandez-Chacon (Departamento de Fisiologia Medica y Biofisica, Univ. Sevilla, Spain) for his invaluable help and teaching on the molecular biology techniques, Maria Luz Montesinos for her kind donation of the penetratin plasmid (from French National Centre for Scientific Research Paris, France), and to Davies L. Davies (Queen's Univ., Ontario, Canada) for his kind donation of the AFPIII.

SLTB Meeting

Posters

Development of cryopreservation procedures based on vitrification in *Mentha* sp. to minimize the growth of endophytic bacteria

V. Cañizares¹, T. Peña¹, C. Martín¹, M.E. González-Benito¹

¹Dpt. of Biotechnology-Plant Biology, E.T.S.I. Agronómica, Alimentaria y de Biosistemas, Universidad Politécnica de Madrid

The conservation of germplasm of cultivated species with vegetative multiplication can be carried out through field collections, in vitro culture (with limited growth) and by cryopreservation. Cryopreservation allows the conservation of plant germplasm in the long term. Successful cryopreservation procedures for mint apices have been obtained by vitrification either using PVS2 or PVS3 vitrification solutions (Senula et al., 2018). However, one important setback in some mint genotypes is the presence of endophytic bacteria. Their presence does not disturb in vitro growth of shoots, but reduces the success of cryopreservation protocols. We have studied the use of the antibiotic cephotaxime in different steps of the cryopreservation protocol for apices of *Mentha aquatica*. The cryopreservation protocol applied was based on the droplet- vitrification procedure, and the results obtained with PVS2 and PVS3 were compared. The antibiotic was included in the media used during cold acclimation or in the recovery media. The use of cephotaxime in the medium used during cold acclimation combined with PVS3 resulted in higher recovery. The use of the antibiotic in the recovery medium decreased the presence of bacterial infection but did not have a significant effect on recovery when the vitrification solution was PVS3.

This work was supported by project AGL2015-64899-C2-1/ MINECO-FEDER

1. Senula A, Büchner D, Keller ERJ, & Nagel M (2018) CryoLetters 39, 345-353

Cryopreservation of in vitro grown shoot tips of strawberry (*Fragaria × ananassa* Duch.) genetic resources by droplet-vitrification

Kotnala Balaraju¹, Young-yi Lee¹, Jae-young Song¹, Jung-yoon Lee¹, Jung-ro Lee¹, Munsup Yoon¹, Haeng-hoon Kim²

¹National Agrobiodiversity Center, NAS, RDA, Suwon 16613, Korea

²Department of Well-being Resources, Sunchon National University

This study describes an efficient and widely applicable droplet-vitrification following cryopreservation for shoot tips of strawberry (*Fragaria × ananassa* Duch.) cvs. 'Wonkyo3114' and 'Gurumi40'. The shoot tips were precultured in Murashige and Skoog (MS) liquid medium supplemented with sucrose (0.3-0.5M). Precultured explants were osmoprotected with loading solution (LS, C4) containing glycerol 20% and sucrose 20% for 40 min and exposed to dehydration solution (B5) containing 40% of glycerol and 40% of sucrose for 40 min at 25°C, and then transferred onto droplets containing 2.5 µl PVS3 on sterilized aluminium foils (4 cm × 0.5 cm) prior to direct immersion in liquid nitrogen (LN) for 1 h. The highest regrowth rate (%) was obtained when shoot tips were precultured with MS + 0.3M sucrose for 40 h at 25°C in both the cultivars. The viability of cooled samples, followed by culturing on NH₄NO₃-free MS medium supplemented with 3% sucrose, 1.0 g/L casein, 1.0 mg/L GA₃, and 0.5 mg/L BA for 5 weeks and then cultured onto MS medium supplemented with 0.5 mg/L GA₃ for 8 weeks obtained more than 55% regrowth rate in cryopreserved shoots tips. This result shows droplet-vitrification would be a promising method for cryostorage of strawberry germplasm.

Keywords: Cryopreservation, Dehydration, Regrowth, Strawberry, Shoot tips

Acknowledgements: This study was carried out with the support of "Development and application of cryopreservation technique for strawberry and Lilum germplasm and quality management for seed base collection (Project No. PJ014294)", National Institute of Agricultural Sciences, Rural Development Administration, Republic of Korea.

1. Benelli C, De Carlo A & Engelmann F (2013) *Biotechnol Adv* 31,175-185
2. Clavero-Ramirez I et al (2005) *Cryo Lett.* 26, 17-24
3. Coste, A et al (2015) *Turk. J. Biol.* 39, 638-648
4. Engelmann F (1997) in *Biotechnology and Plant Genetic Resources* (eds) Callow JA, Ford-Lloyd BV & Newbury HJ, CAB International 119-161

Droplet-vitrification method for shoot tips of *Physalis Angulata* L.

F Romo-Paz¹, L Delgado-Aceves¹, L Portillo¹, R Folgado²

¹University of Guadalajara, Department of Botany and Zoology - CUCBA, 2100 Camino Ramon Padilla Sanchez, Nextipac, Jal, 45200, Mexico

²Botanical Division, The Huntington Library, Art Collections, and Botanical Gardens, 1151 Oxford Road, San Marino, CA 91108, USA

Physalis angulata is a species of the Solanaceae family, of edible and medicinal fruit. Its phytochemical constituents (physalins and withanolides) have antiparasitic, anti-inflammatory, antimicrobial, and antitumor activity. Indeed, this validates their traditional medicinal use and demonstrates its tremendous potential for further development within the pharmaceutical industry (1). The natural distribution of the species has been affected by different factors, such as modern agriculture, and the lack of adequate protocols reduces the ex-situ conservation opportunities (2). Cryopreservation is an ex-situ conservation tool that ensures the maintenance and preservation of the original population variability (3). The present study focused on optimizing the droplet-vitrification technique for apical buds of *P. angulata*, from in vitro plants. Thus, apical shoot tips of 1 mm size were excised from 4-week-old micropropagated plantlets. Dissected meristems were exposed to loading solution for 20 min at room temperature, dehydrated with PVS2 for different times (0-75 min) at 0°C, transferred to aluminum foil strips and directly plunged into liquid nitrogen. For re-warming, aluminum strips were rinsed in unloading solution for 20 min at room temperature. Explants were transferred to recovery medium and kept in dark for one week and two more weeks under low light conditions (5 $\mu\text{mol}\cdot\text{m}^{-2}\cdot\text{s}^{-1}$). Optimal results were obtained after 30 min of exposure to PVS2, whereas shorter or longer dehydration times resulted in lower viability. Shoot tips regrew within one week, and new shoots regenerated within five weeks. Plant recovery was recorded two months after the re-warming, resulting in 90% of re-warmed meristems regenerated into a whole plant. This preliminary study showed that the droplet-vitrification method is proper for *P. angulata*. Further investigations will be performed in other *Physalis* species to assure the long-term preservation of these valuable plants.

1. Renjifo-Salgado E & Vargas-Arana (2013). Boletín Latino Americano Caribe Plant Med Aromat 12: 431-45
2. Paunescu A. (2009) Rom. Biotchnol. Lett. 14: 4095-4103
3. Engelmann F (2010) In Vitro Cell. Dev. Biol. Plant. 47: 5-16

Cryoconservation of hop pollen (*Humulus lupulus* L.)

M Faltus*¹, P Svoboda²

¹Research Institute of Crop Production, Prague, Czech Republic

²Hop Research Institute, Co., Ltd., Žatec, Czech Republic

The hop plant, *Humulus lupulus*, L., is a dioecious perennial species, and only female clones are used for beer brewing. Cryopreservation of pollen is an additional way to conserve many species. In particular, it can be used as an alternative strategy to preserve the genetic variation and minimize problems of asynchronous flowering among accessions preserved in a germplasm bank (2017).

Storage of pollen not only effectively overcomes the obstacles in crossing of parents flowering at different times and in different geographical locations, but also is an effective means to preserve the genetic diversity of plants. Multi-branched panicles of selected individuals of male hop clones (12/00, 12/06, 19/07) were collected in July 2019. Hop pollen grains were spontaneously released from panicles and collected into plastic test tubes in laboratory conditions. Thermal analysis of hop pollen was performed using differential scanning calorimeter (DSC) Q2000 (TA Instruments, USA) with refrigerated cooling system (RCS) in the temperature range from -90 to +20°C. The cooling rate was 10°C/min. Temperature-modulated DSC method was used during warming cycle with warming rate of 1°C/min. Temperature modulation was performed at 1°C amplitude of modulation and 60 second period. Aluminium, hermetically sealed pans were used, sample size ranged from 5 to 20 mg and the purge gas was nitrogen. No significant endothermic or exothermic events were detected in all genotypes tested. On the other hand, the glass transitions were detected in all samples during warming cycles and they ranged from -35 °C to -10 °C. The half-height of sample glass temperature was -18 °C, -20 °C and -28 °C in clones 19/07, 12/06 and 12/00, respectively. The determined thermal characteristics of all hop clones tested make their cryopreservation possible.

Source of Funding: This study was supported by the research projects QK1910277 and MZE RO0418 of the Ministry of Agriculture of the Czech Republic. Genetic resources, is a part of “National Program of Conservation and Utilization of Genetic Resources in Plants and Biodiversity” (MZe 33083/03-300_6.2.1) issued by Czech Ministry of Agriculture.

1. Changes of pollen viability of ornamental plants after long-term preservation in a cryopreservation pollen bank. Cryobiology 89 (2019) 14–20

Large scale freezing and thawing of 1Litre of alginate encapsulated HepG2 cell biomass using a cryobag: a viable proposition for use with the UCL Bioartificial Liver (BAL)

Tom Brookshaw¹, Eloy Erro¹, Maooz Awan¹, Tamnia Islam¹, Alfie Watt¹, Joana Mendonça Da Silva¹, Barry Fuller², Clare Selden¹

¹UCL Institute for Liver and Digestive Health, UCL – Royal Free Hospital Campus, UCL Medical School, London, NW3 2PF, United Kingdom

²Dept. of Surgery, UCL Medical School, Royal Free Hospital, London, NW3 2QG, United Kingdom

For rapid delivery of the UCLBAL to patients, robust cryopreservation of large volumes (>1L) alginate encapsulated liver spheroids (AELS) and optimal cryopreservation protocols are required. Controlled rate freezing provides an average cooling rate of $-0.35^{\circ}\text{C}/\text{min}$ for small volume samples (max $\sim 100\text{ml}$), however larger volumes are not routinely used. Multiple large scale samples could be cooled simultaneously however, the effect on the cooling rates may differ spatially due to LN2 vapor distribution. Warming of the biomass also requires optimization. Both processes significantly affect the post-cryopreservation viability and performance of AELS.

Cryobags filled with 20% glycerol were temperature monitored with thermocouples. 20% glycerol was used as a mimic of hydrogel beads, with the same thermal histories. Filled cryobags were cooled in a CRF (Kyro750-Planer plc). AELS recovery was assessed in cryopreserving cell beads in the centre of a cryobag filled with empty alginate beads making 1L volume. Warming consisted of warming cryobag from -150°C to -80°C followed by submersion and agitation in a 37°C waterbath. AELS were re-cultured to recover. Cell number and metabolic viability were assessed by nuclei counts and fluorescent staining of vital dyes (PI & FDA).

Cooling rates for single cryobag samples on each rack tier were; top: $-0.3483^{\circ}\text{C}/\text{min}$, middle: $-0.3566^{\circ}\text{C}/\text{min}$ & bottom: $-0.3495^{\circ}\text{C}/\text{min}$, $n=5$. For 3 cryobags cooled simultaneously; top: $-0.3529^{\circ}\text{C}/\text{min}$, middle: $-0.3496^{\circ}\text{C}/\text{min}$ & bottom: $-0.3403^{\circ}\text{C}/\text{min}$, $n=5$. No significant difference was observed between either rack positions or individual/multiple cryobags simultaneously. Thawing of cryobags was completed consistently within 10 minutes. Recovery of AELS successfully restored pre-freeze viability and functionality.

Cryopreservation of 3 x 1Litre cryobags was achievable, providing an efficient and cost effective process. AELS placed centrally within the cryobag were successfully recovered; large scale tests with full volumes are underway.

Does DMSO elicit toxicity in cryopreservation of liver cell derived organoid cultures?

E Erro¹, M Awan¹, E Forster-Brown¹, A Watt¹, S Chalmers¹, B Fuller², C Selden¹

¹UCL Institute for Liver and Digestive Health, UCL – Royal Free Hospital Campus, UCL Medical School, London, NW3 2PF, United Kingdom

²Dept. of Surgery, UCL Medical School, Royal Free Hospital, London, NW3 2QG, United Kingdom

Liver disease kills >12000 people p.a. in UK; deterioration from liver failure is often rapid, so any solution must be readily available. A BioArtificial Liver machine (BAL), can provide liver function allowing a patient's liver to repair and regenerate. Cryopreservation of a BAL will enable fast delivery to patients. DMSO is widely used, with varying reports of cell toxicity (1,2), but with little data on its effects on cell-organoids. Since thawing of large volume cryopreserved organoid biomass is lengthy, and leads to exposure of AELs to max 20C, we explored DMSO toxicity in organoid culture mimicking a typical thawing protocol.

Alginate encapsulated cell spheroids (AELS) cells at $13.2 \pm 0.14 \times 10^6$ cells/ml beads, viability 96.9%, were exposed to 12% DMSO, 38% Viaspan for 10min at 0C, 20C or 37C. Cell viability was assessed immediately after DMSO exposure; viable cell number on re-culture for 24h with 40% DMSO as a positive control.

There was no detrimental effect of 12%DMSO at 0C, 24C or 37C for 10 min after immediate exposure; viability was 97, 97 and 96% respectively; after 40%DMSO, viability was 53.46%. Viable cell numbers at 24h were: at 0C 14.1×10^6 cells/ml beads, n=3; at 24C, 13.9, n=3; at 37C $14.0 \pm 1.8 \times 10^6$ cells/ml beads, mean $\pm$ -SD, with viability >97%. In contrast 40% DMSO exposure resulted in loss of viable cell numbers to 0.378×10^6 cells/ml, viability 7.5%.

Liver cell-derived cell organoids can be exposed to temperatures as high as 37C without compromise to viable cell number. As expected DMSO at high concentration was immediately toxic. These data indicate that a protocol for organoid thawing in volumes of >1Litre, can be achieved, suitable for a BAL biomass clinical protocol.

1. Galvao J et al (2014) FASEB J. 28, 1317–1330. doi:10.1096/fj.13-235440.

2. Liu Y et al (2017) FEBS open bio. 7(4), 485-494

SLTB Meeting

Video Presentation

Short-term hypothermic storage supports maintenance of transplantable hematopoietic stem cells

F Aerts-Kaya^{1,2}, B Pervin^{1,2}, A Mammadova^{1,2}, G Wagemaker², D Uckan-Cetinkaya^{1,2}

¹Hacettepe University, Graduate School of Health Sciences, Dept of Stem Cell Sciences, Ankara, Turkey

²Hacettepe University, Center for Stem Cell Research and Development, Ankara, Turkey

Hematopoietic Stem Cells (HSC) can be isolated from bone marrow, mobilized peripheral blood and umbilical cord blood (UCB) and give rise to all mature blood cells. Cryopreservation of HSCs include the use of Dimethyl Sulphoxide (DMSO) to protect cells during freezing, but may result in cellular toxicity during thawing and infusion in patients.

With the increase of clinical HSC gene therapy, the need for novel short-term culture and storage protocols has been increased. Short-term storage of HSCs under hypothermic conditions could also provide an alternative to DMSO-cryopreservation and facilitate transport of cellular products.

SUL-109 (Sulfateq) promotes storage of several cell lines under hypothermic conditions. Here, we cultured human CD34+ UCB cells and lineage depleted (Lin⁻) Balb/c BM cells up to 7 days in serum-free HSC expansion medium with hematopoietic growth factors. SUL-109 containing cultures were stored at 4°C for 3-14 days. UCB cells were tested for viability, cell cycle and reactive oxygen species (ROS). DMSO-cryopreserved Lin⁻ BM cells or Lin⁻ BM cells maintained for 14 days at 4°C were transplanted into RAG2^{-/-} Balb/c mice and engraftment was followed for 6 months.

Hypothermic storage of CD34+ UCB and Lin⁻ BM cells in presence of SUL-109 resulted in a protective effect on viability, increased numbers of CD34+ UCB cells in G0/G1 phase, and decreased levels of ROS. Lin⁻ BM cells maintained for 14 days at 4°C in presence of SUL-109 retained their long-term engraftment potential, although not to the same extent as DMSO-cryopreserved cells.

These data show that SUL-109, most likely through modulation of ROS levels, protects transplantable, long-term engraftment supporting HSCs during short-term storage under hypothermic conditions and may be used as an alternative to short-term HSC cryopreservation.

